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Summary 
 
The Pentose Phosphate Pathway (PPP) fulfils two unique functions: (i) the 
formation of ribose-5-phosphate (R5P) for the synthesis of nucleotides, RNA and DNA, 
supporting cell growth and proliferation; and (ii) the formation of the reduced form of 
nicotinamide adenine dinucleotide phosphate (NADPH). NADPH carries chemical 
energy in the form of reducing power, being essential to the cellular oxidative defense 
system and is also the universal reducing agent in many anabolic pathways, such as 
cholesterol and lipid synthesis and fatty acids chain elongation. The PPP comprises two 
separate branches: (i) an oxidative, non-reversible branch, and (ii) a non-oxidative, 
reversible branch. The oxidative branch primarily depends on glucose 6-phosphate 
dehydrogenase (G6PD), whereas transaldolase (TALDO) is the rate-limiting enzyme for 
the non-oxidative branch. Although the oxidative branch of the PPP is recognized as the 
source of NADPH and R5P, the overall contribution of the non-oxidative branch to 
metabolism and cell survival is poorly understood.  
Metabolism of glucose through the PPP influences the development of diverse 
pathologies.  Deficiency of the PPP enzyme G6PD represents the most common genetic 
defect in humans and leads to NADPH depletion in red blood cells (RBC), predisposing 
to oxidative stress-induced hemolytic anemia. Recently, two new defects in the PPP 
were described: ribose-5-phosphate isomerase (RPI) deficiency and transaldolase 
(TALDO) deficiency. The first defect is associated with progressive 
leukoencephalopathy and mild peripheral neuropathy. The metabolic profile of the 
disease is associated with elevated levels of ribitol and arabitol in the brain, as showed 
by magnetic resonance spectroscopy (MRS), urine, plasma and cerebrospinal fluid 
(CSF). In contrast, TALDO deficiency is associated with liver symptoms, while other 
organs are affected to a variable degree. The metabolic phenotype of the disease is 
characterized by increased urinary concentrations of the polyols: erythritol, arabitol, 
ribitol, sedoheptitol, perseitol and the sugars: sedoheptulose and mannoheptulose, as 
well as sedoheptulose-7-phosphate. 
The profound influence of TALDO on NADPH levels, mitochondrial 
dysfunction and oxidative stress is ascribed to the blocked recycling of R5P to glucose 
6-phosphate (G6P) and to the proposed linkage to aldose reductase (AR) that converts 
the accumulated C5-sugar phosphates to C5-polyols at the expense of NADPH. 
Mitochondrial dysfunction associated to TALDO deficiency leads to liver disease 
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progressing from non-alcoholic fatty liver disease (NAFLD) to non-alcoholic 
steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma (HCC). Therefore, 
TALDO deficiency can account for liver disease of variable severity. 
The diagnosis of the PPP deficiencies is possible by biochemical evaluation of 
polyols’ and sugars’ profiles in body fluids.  Abnormal concentrations of these 
compounds occur in a number of pathological conditions such as diabetes mellitus, 
renal and liver disease and several inborn errors of carbohydrate metabolism, such as 
galactosemia. Therefore, it is necessary to take into account the variability of metabolic 
profiles and to understand their meaning. 
Along the thesis, it is our goal to revise the metabolic pathway of pentose 
phosphates and its implication in the associated disease states. Furthermore, the 
development and validation of the analytical methods (GC-FID and GC-MS) will be 
presented and discussed. We will also present our preliminary results upcoming from 
two separated studies, focused on the characterization of the PPP intermediate 
metabolites profile in (1) pre-selected cases with unexplained hepatosplenomegaly 
and/or liver dysfunction in a pediatric population; and (2) in adult patients with liver 
dysfunction (NAFLD or AFLD). We hope to find new biomarkers and metabolic signs 
which may open new perspectives of research for better understanding liver 
dysfunction. 
Interesting data is described, in the pediatric population, where a patient with an 
isolated sedoheptulokinase (SHPK) deficiency is reported. All the subsequent studies, 
some still in course, seem to confirm this new defect in the PPP.  
In the adult population our findings point to the putative importance of polyols 
as possible biomarkers of liver dysfunction progression. 
 
Keywords: Pentose Phosphate Pathway; ribose-5-phosphate isomerase deficiency; 
transaldolase deficiency; non-alcoholic fatty liver disease; sedoheptulokinase deficiency. 
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A via das pentoses fosfato tem dois objectivos principais: (i) a formação de 
ribose-5-fosfato (R5P) para a síntese de nucleótidos, ARN e ADN, essenciais para o 
crescimento e proliferação celular; e (ii) a redução de nicotinamida adenina dinucleótido 
fosfato (NADPH). A NADPH transporta energia química sob a forma de poder redutor, 
sendo essencial para o sistema de defesa oxidativo das células e sendo ainda o agente 
redutor universal de inúmeras reacções anabólicas, tais como a síntese de colesterol e 
lípidos e o prolongamento das cadeias dos ácidos gordos. 
A via das pentoses fosfato é constituída por dois ramos: (i) um ramo oxidativo, 
não reversível, e (ii) um ramo não-oxidativo, completamente reversível. O ramo 
oxidativo é dependente da actividade da enzima glucose-6-fosfato desidrogenase 
(G6PD), enquanto a transaldolase (TALDO) é a enzima limitante do ramo não-
oxidativo. Apesar do reconhecido papel do ramo oxidativo da via das pentoses fosfato 
como fonte de NADPH e R5P, a contribuição da via não-oxidativa no metabolismo e 
sobrevivência celular é pouco conhecida. 
 O metabolismo da glucose na via das pentoses fosfato influencia o 
desenvolvimento de diversas patologias. A deficiência em G6PD é o defeito genético 
mais comum na população humana, levando a níveis reduzidos de NADPH nos 
eritrócitos e predispondo ao aparecimento de anemia hemolítica induzida por stress 
oxidativo. Recentemente, foram descritas duas novas deficiências enzimáticas na via 
das pentoses fosfato: a deficiência em ribose-5-fosfato isomerase (RPI) e a deficiência 
em transaldolase (TALDO). A primeira deficiência enzimática está associada a 
leucoencefalopatia progressiva e ligeira neuropatia periférica. O perfil metabólico da 
doença revela níveis elevados dos polióis: ribitol e arabitol no cérebro, tal como 
demonstrado por ressonância magnética, na urina, plasma e líquido cefalorraquidiano 
(LCR). Por outro lado, a deficiência em transaldolase está associada a alterações 
hepáticas, havendo um grau variado de comprometimento por parte de outros órgãos. O 
fenótipo metabólico desta deficiência está associado à excreção de níveis elevados dos 
polióis: eritritol, arabitol, ribitol, sedoheptitol, perseitol e dos açúcares: sedoheptulose e 
manoheptulose, bem como de sedoheptulose-7-fosfato. 
A forte influência da transaldolase nos níveis de NADPH em situações de 
disfunção mitocondrial e stress oxidativo é atribuída ao bloqueio da reciclagem da 
glucose-6-fosfato a partir da ribose-5-fosfato e à hipotética ligação à actividade de 
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aldoses redutases (AR), responsáveis pela conversão dos açúcares-C5-fosfatados a C5- 
polióis, às custas de NADPH. A disfunção mitocondrial associada à deficiência em 
transaldolase leva a uma doença hepática progressiva que se inicia com o aparecimento 
do fígado gordo não alcoólico (NAFLD), passando a esteatohepatite não alcoólica 
(NASH), cirrose e carcinoma hepatocelular (CHC). Assim, a deficiência em 
transaldolase está associada a doença hepática de variado grau de severidade. 
O diagnóstico dos defeitos da via das pentoses fosfato é possível pela análise dos 
perfis bioquímico dos açúcares e polióis nos fluidos biológicos. Concentrações elevadas 
destes compostos aparecem em diversas situações patológicas, tais como a diabetes 
mellitus, a doença renal e hepática e vários erros hereditários do metabolismo dos 
hidratos de carbono, tais como a galactosemia. Assim, torna-se imperativo ter em conta 
a grande variabilidade de perfis metabólicos e o conhecimento dos seus significados.  
Ao longo desta tese, é nosso objectivo fazer uma revisão sistematizada da via 
das pentoses fosfato e a sua implicação em estados de doença. Será ainda apresentado e 
discutido o desenvolvimento e validação dos métodos cromatográficos (GC-FID e GC-
MS) desenvolvidos. Finalmente, apresentaremos os resultados preliminares de dois 
estudos, iniciados com o objectivo de caracterizar os metabolitos intermediários da via 
das pentoses fosfato em (i) uma população pediátrica de casos pré-seleccionados com 
hepatoesplenomegália de causa desconhecida e/ou com disfunção hepática; e (ii) uma 
população de adultos com disfunção hepática (fígado gordo não alcoólico ou doença 
hepática devida ao abuso do consumo de álcool). Esperamos descobrir novos 
biomarcadores ou alterações metabólicas importantes, que possam abrir a porta a 
futuros estudos para melhor compreender a disfunção hepática. 
No estudo efectuado na população pediátrica são apresentados resultados 
interessantes de um doente em que se descreve pela primeira vez um défice isolado da 
enzima sedoheptulose cinase (SHPK). Todos os estudos subsequentes, alguns ainda em 
curso, apoiam a descoberta desta nova deficiência enzimática na via das pentoses 
fosfato. 
No estudo da população adulta com disfunção hepática, os nossos resultados 
apontam para uma possível importância do perfil dos polióis como biomarcadores da 
progressão da disfunção hepática.  
Palavras-chave: Via das pentoses fosfato; deficiência em ribose-5-fosfato isomerase; 
deficiência em transaldolase; fígado gordo não alcoólico; deficiência em sedoheptulose cinase. 
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1. General aims 
 
The Pentose Phosphate Pathway (PPP) comprises two separate branches: (i) an 
oxidative, non-reversible branch, and (ii) a non-oxidative, fully reversible branch, 
fulfilling two major functions: (a) the formation of ribose-5-phosphate (R5P) for the 
synthesis of nucleotides, supporting cell growth and proliferation; and (b) the reduction 
of nicotinamide adenine dinucleotide phosphate (NADPH). NADPH is used as the 
reducing agent in many biosynthetic reactions and is also used in the cellular oxidative 
defense system, protecting against oxidative stress either directly by neutralizing 
reactive oxygen species (ROS) or indirectly via regenerating reduced glutathione (GSH) 
from its oxidized form GSSG.  
The metabolism of glucose through the PPP influences the development of 
diverse pathologies.  Deficiency of the first enzyme of the oxidative branch of the PPP, 
glucose-6-phosphate dehydrogenase (G6PD), represents the most common genetic 
defect in humans and causes the depletion of NADPH in red blood cells (RBC), 
predisposing to oxidative stress-induced hemolytic anemia.  
Recently, two new defects in the PPP, namely in the non-oxidative branch, have 
been described. The first defect, ribose-5-phosphate isomerase (RPI) deficiency, was 
described in 1999 by Marjo van der Knaaps’ group, in a patient with a slowly 
progressive leukoencephalopathy with mild peripheral polyneuropathy, who remains 
until the present date, the only patient described as having this enzymatic defect. The 
second defect is transaldolase (TALDO) deficiency. The first TALDO deficient patient 
description was made by Verhoeven and co-workers in 2001. The patient presented 
clinically with liver cirrhosis and hepatosplenomegaly, thrombocytopenia and 
dysmorphic features. Since this first TALDO deficient patient description, 22 new cases 
have been described in the literature. 
With the expanding number of newly diagnosed TALDO deficient patients and 
the description of the only RPI deficient patient, the investigations on these inherited 
metabolic defects of the PPP have increased, leading to better knowledge of their 
biochemical significance and clinical phenotypes. However, many questions on the 
pathophysiology of these defects remains unknown, and research regarding these 
questions has been initiated leading to this master thesis with the following three major 
goals.  
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 The development and validation of a GC-FID method to allow the qualitative 
and quantitative analysis of polyols’ and sugars’ profile in healthy people and 
patients; 
 
 The characterization of the PPP’s intermediate metabolites pattern in an adult 
population of patients with either non-alcoholic fatty liver disease (NAFLD) or 
alcoholic fatty liver disease (AFLD), in order to find new biomarkers and/or 
metabolic signs that may enlighten the understanding of their liver dysfunction; 
 
 The characterization of the PPP’s intermediate metabolites pattern in pre-
selected cases, in a pediatric population with unexplained hepatosplenomegaly 
and/or liver dysfunction, to discover new putative patients with defects in the 
PPP. 
 
2. Outline of the thesis 
 
In chapters 1 and 2, the aims of the thesis and a comprehensive introduction to 
the pentose phosphate pathway function and malfunction are presented. In addition to 
the previously cited deficiencies (RPI and TALDO deficiencies), a brief introduction of 
two other conditions occurring in (i) a parallel pathway linked with the PPP, the 
glucoronate-xylulose pathway, originating the benign condition essential pentosuria, 
and (ii) a recently described enzymatic defect in the L-arabitol dehydrogenase, 
originating L-arabinosuria, are presented. These two conditions present, as do the RPI 
and TALDO deficiencies, abnormal sugars’ and polyols’ profile, which are easily 
spotted by the GC-FID method developed and presented (chapter 3). Also, in the last 
part of the general introduction, a link between the PPP and cancer metabolism is 
presented, in order to allow a better understanding of some of the results obtained in 
chapter 4. 
 
In chapter 3 the development of the analytical methods where, among other 
parameters, the conditions of the optimized gas chromatographic systems (GC-FID and 
GC-MS), the qualitative and quantitative data involved in the validation of the GC-FID 
Aims and outline of the thesis 
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method, plus the preliminary results for the building up of the laboratory’s reference 
values are described.  
 
In chapter 4 the study of an adult population with liver dysfunction is presented. 
The pre-selected cases enrolled in this study had a liver disease due to either an 
unknown cause (Non-alcoholic Fatty Liver Disease) or to alcohol abuse (Alcoholic 
Liver Disease). The main goal of this chapter was the enlightenment and/or 
establishment of a link between the biochemical intermediate metabolites of the PPP 
and liver dysfunction. In order to answer our hypothesis, we searched for new 
biomarkers and metabolic signs that could lead to a better understanding of the liver 
dysfunction interplay with cell processes. With this study we can postulate a crucial role 
of the PPP’s intermediate metabolites pattern, in assessing liver disease progression, 
once the pattern of these compounds appears to be altered in advanced or 
decompensated forms of liver disease.  
 
In chapter 5 the study of the urinary sugars’ and polyols’ profile, in a pediatric 
population presenting liver dysfunction of unknown cause, is presented. In the last 
twelve years, several cases of patients with defects in the PPP’s enzymatic mechanism 
(RPI deficiency and TALDO deficiency) have been found. Also, these new disorders 
have been the thrust for screening of new patients. In this chapter, it will be described 
the first patient, to our knowledge, with an isolated form of sedoheptulokinase (SHPK) 
deficiency, proving the importance of this method in newborn screening of inherited 
errors of metabolism (IEM) and also for the evaluation of liver dysfunction progression 
and/or severity. 
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General introduction 
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1. Introduction 
 
1.1. The Pentose Phosphate Pathway 
 
The pentose phosphate pathway (PPP), also known as phosphogluconate 
pathway or hexose monophosphate shunt, is a multifunctional pathway that comprises 
two separated branches, with two specific roles: i) an oxidative, non-reversible branch 
that allows reduction of nicotinamide adenine dinucleotide phosphate (NADP
+
) while 
glucose-6-phosphate (G6P) is oxidized to a ketopentose phosphate (ribulose-5-
phosphate; Ru5P) and carbon dioxide (CO2); and ii) a non-oxidative, reversible branch 
that connects pentose phosphates to glycolytic intermediates [1, 2]. The PPP does not 
require oxygen and does not generate ATP. In the oxidative branch G6P is oxidized to 
Ru5P by two successive reactions. First, the carbon 1 of G6P is oxidized from an aldol 
to an internal ester (lactone) by glucose-6-phosphate dehydrogenase (G6PD) and 6-
phosphoglucono-δ-lactone is formed. The lactone is hydrolyzed to 6-phosphogluconate 
(the free acid) by a specific lactonase (6-phosphogluconolactonase) and then 6-
phosphogluconolactone dehydrogenase (6PGD) further oxidizes carbon 1 to CO2 
leaving the 5-carbon sugar, Ru5P [2]. Two molecules of NADPH (both formed in the 
two dehydrogenases reactions) and one molecule of Ru5P are the end products of the 
oxidative phase in the PPP, as shown in Fig. 1.  
Ru5P is necessary for the biosynthesis of nucleic acids (RNA and DNA). Higher 
rates of nucleic acids biosynthesis occurs in growing and regenerating tissues, like the 
bone marrow, skin and intestinal mucosa, as well as in tumors. The PPP ends, in many 
tissues, with the formation of ribose 5-phosphate (R5P), CO2 and two molecules of 
NADPH and two H
+
. 
NADPH carries chemical energy in the form of reducing power. NADPH is used 
almost universally as a major cellular reducing agent in many biosynthetic pathways, 
being also vital to the cellular oxidative defense system, counteracting the damaging 
effects of reactive oxygen species (ROS) either directly or indirectly via the 
regeneration of reduced glutathione (GSH) from its oxidized form (GSSG) [3], as 
shown in Fig. 2. 
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Fig. 1. The oxidative and non-oxidative phases of the pentose phosphate pathway. NADP
+
, 
nicotinamide adenine dinucleotide phosphate; NADPH, reduced form; 1) glucose-6-phosphate 
dehydrogenase; 2) 6-phosphogluconolactonase; 3) 6-phosphogluconolactone dehydrogenase; 4) 
ribulose-5-phosphate epimerase; 5) ribose-5-phosphate isomerase; 6) transketolase; 7) 
transaldolase.  
 
 
Fig. 2. The glutathione redox cycle. The reduced and active form of glutathione (GSH) converts 
hydrogen peroxide into water with the help of glutathione peroxidase (GPX). The oxidized form 
of glutathione (GSSG) is reduced by glutathione reductase (GR) back to GSH in the presence of 
its cofactor, the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH). 
 
In mammalian tissues actively synthesizing fatty acids and steroids (e.g. 
mammary gland, adrenal cortex, liver and adipose tissue), NADPH is the major 
reducing power in these anabolic pathways. NADPH is used in the reduction of the 
double bonds and carbonyl groups of intermediates in the synthetic process. In tissues 
General introduction 
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less active in synthesizing fatty acids (e.g. skeletal muscle), the PPP is virtually absent 
[2].  
G6PD is the principal source of NADPH for the antioxidant system, but not the 
only one. Three other enzymatic sources for NADPH reductions are known: i) 6-
phosphogluconolactone-dehydrogenase (6PGD); ii) malate dehydrogenase (MDH; also 
known as malic enzyme); and iii) cytoplasmic isocitrate dehydrogenase (ICDH) [4].  
In tissues that require primarily NADPH rather than R5P, the non-oxidative 
branch is of major importance and is responsible for the recycling of pentose phosphates 
to G6P. The first reaction of the non-oxidative phase begins with Ru5P being either 
epimerized to xylulose-5-phosphate (Xu5P) or isomerized to ribose-5-phosphate (R5P). 
Then, in a series of rearrangements of the carbon skeletons, six five-carbon sugar 
phosphates are converted to five six-carbon sugar phosphates, completing the cycle and 
allowing continued oxidation of G6P with production of NADPH, as shown in Fig. 3 
[2].  
 
 
Fig. 3. Reversible (non-oxidative) reactions of the pentose phosphate pathway. Six pentoses 
(5C) originate five hexoses (6C). Adapted from [2]. 
 
There are two enzymes unique to the PPP: transketolase (TKT) and transaldolase 
(TALDO). TKT is the enzyme responsible for the transfer of C-1 and C-2 of Xu5P to 
R5P, forming the seven-carbon product (sedoheptulose-7-phosphate; S7P) and a three-
carbon fragment (glyceraldehyde-3-phosphate; G3P). After this first step, TALDO 
catalyzes the removal of a three-carbon fragment from S7P and condenses it with G3P, 
forming fructose-6-phosphate (F6P) and the tetrose erythrose-4-phosphate (E4P). After 
this step TKT acts again, this time forming F6P and G3P from E4P and a new molecule 
of Xu5P. Two molecules of G3P, formed by two cycles of these reactions, can be 
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converted to a molecule of fructose-1,6-bisphosphate (FBP) as in gluconeogenesis, and 
finally fructose-1,6-biphosphatase 1 (FBPase-1) and phosphohexose isomerase can 
convert FBP back to G6P. 
The deficient metabolism of glucose through the PPP is associated with 
development of diverse pathologies. Deficiency of the PPP enzyme G6PD represents 
the most common genetic defect in humans, accounting for more than 400 million 
people, and causes the depletion of NADPH in red blood cells (RBC), predisposing to 
oxidative stress-induced hemolytic anemia [5]. Recently, two new defects in the non-
oxidative branch of the PPP were discovered: ribose-5-phosphate isomerase (RPI) 
deficiency [6] and transaldolase (TALDO1) deficiency [7]. Other defects in metabolic 
pathways linked to the PPP are known for some time. L-Xylulose reductase, an enzyme 
responsible for the conversion of L-xylulose to L-xylitol, is an important enzyme in the 
glucoronate-xylulose pathway (GXP). D-Xylulose can, through the action of 
xylulokinase, produce Xu5P, and therefore do the connection with the PPP. Also, 
Diabetes Mellitus and Galactosemic patients have fingerprint profiles of sugars and 
polyols, and although the deficits in these diseases are not in the PPP, accumulation of 
characteristic sugars and polyols are the underlying cause of some of the clinical 
symptoms and health related problems observed in those disorders.   
 
 
1.2.  Glucose-6-phosphate dehydrogenase (G6PD; EC 1.1.1.49) 
G6PD is the first and rate-limiting enzyme of the oxidative phase of the PPP. 
The main role of this enzyme is the provision of reducing power to all cells in the form 
of reduced nicotinamide adenine dinucleotide phosphate (NADPH) [3] rather than 
glucose utilization (G6PD accounts for less than 10% of glucose metabolism) [8]. 
G6PD is a housekeeping enzyme encoded by a housekeeping gene. The gene is 
expressed in all cells of the body, and although G6PD is a typical cytoplasmic enzyme, 
some activity is associated with peroxisomes in liver and kidney cells [8]. The G6PD 
deficiency (OMIM #305900) is an X-linked, hereditary genetic defect caused by 
mutations in the G6PD gene. The G6PD gene (ID 2539) is located on the telomeric 
region of the long arm of the X chromosome (Xq28 region), and consists of 13 exons. 
The gene was firstly cloned in 1986 by Persico and co-workers, who isolated cDNA 
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clones from HeLa cells, SV40-transformed human fibroblasts, human placenta and 
human teratocarcinoma cell lines, although without mapping the exact localization of 
the functional sites for G6P and NADP
+
 binding sites [9]. 
The G6PD protein, in its active state, consists of homodimers and 
homotetramers, the proportion of both being pH dependent. The primary structure of the 
single subunit has been determined from cDNA sequence and consists of 515 amino 
acids [10].  
G6PD deficiency was discovered as the result of a series of investigations 
performed to understand the reasons behind the development of hemolytic anemia in 
some individuals treated for malaria with 6-methoxy-8-aminoquinoline drug 
(primaquine) [7, 8]. Primaquine is just one of many drugs that shorten the RBC lifespan 
in G6PD deficient patients [10]. 
More than 400 biochemical variants of G6PD have been described according to 
measurements of residual enzyme activity, electrophoretic mobility, physicochemical 
properties (thermostability and chromatographic behavior) and kinetic variables 
(concentration of substrate needed for an enzymatic reaction at half the maximum speed 
(Km) for G6P; Km for NADP
+
 and pH dependence).  
About 140 mutations in the G6PD gene have been reported, most of which are 
single-base substitutions leading to amino acid replacements [3]. In 1967, the World 
Health Organization (WHO) made the first recommendations to classify the G6PD 
deficient variants, using only the measurements of residual enzyme activity and 
electrophoretic mobility for biochemical characterization of the enzyme. In 1989 the 
same organism expanded the biochemical characteristics of the enzyme [13]. The 
variants were classified in five classes: i) class I variants are severely deficient and 
patients are associated with a chronic non-spherocytic haemolytic anaemia (CNSHA); 
ii) class II variants have less than 10% of residual enzyme activity but without CNSHA 
(include the common Mediterranean and common severe oriental variants); iii) Class III 
variants are moderately deficient with 10-60% residual enzyme activity (include the 
common African form); iv) Class IV variants have normal enzyme activity; v) and in 
Class V the enzyme activity is increased [13]. 
G6PD deficient individuals may be asymptomatic throughout life. The illness 
generally manifests as: (1) chronic non-spherocytic hemolytic disease; (2) acute 
haemolytic anaemia or (3) neonatal jaundice triggered by infection, administration of 
oxidative drugs or ingestion of fava beans [3]. 
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Fig. 4. Schematic presentation of the oxidative phase of the pentose phosphate pathway in 
glucose-6-phosphate dehydrogenase (G6PD) deficiency. 1) 6-phosphogluconolactonase; 2) 6-
phosphogluconolactone dehydrogenase. G6PD deficiency leads to reduced levels of NADPH. 
NADPH is crucial for the detoxification of hydrogen peroxide (H2O2) in all cells, but 
particularly in RBC. NADPH is the substrate of glutathione reductase (GR), the enzyme 
responsible for catalyzing the regeneration of GSSG to GSH, when it has been oxidized by 
glutathione peroxidase (GPX). 
 
 
1.3.  Ribose-5-phosphate isomerase (RPI; EC 5.3.1.6) 
RPI catalyzes the reversible conversion between the ketose R5P and its isomer, 
the aldose Ru5P. The enzyme exists as two distinct proteins, RpiA and RpiB. RpiA is 
present in nearly all organisms, while RpiB is present in bacteria and trypanosomatids. 
Although the same reaction is catalyzed by both proteins, they show no sequence or 
structural homology [14]. 
The human RPIA gene (ID 22934) is located in the short arm of chromosome 2 
(2p11.2 region) and is highly conserved in most organisms. Mutations in this gene cause 
ribose-5-phosphate isomerase deficiency (RPI deficiency, OMIM #608611). In 1999, 
van der Knaap and co-workers [15] described a patient with slowly progressive brain 
white matter disease (leukoencephalopathy) of unknown origin, and mild peripheral 
polyneuropathy. The patient had no organomegaly or dysfunction of internal organs. 
The usual metabolic screening done to this patient revealed no abnormal results in the 
amino acids’, organic acids’, purines’, pyrimidines’, oligosaccharides’ and 
mucopolysaccharides’ patterns [15]. The only altered results were marked elevations of 
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arabitol and ribitol in urine, plasma and cerebrospinal fluid (CSF). A defect in the PPP 
was hypothesized and in 2004 Huck and co-workers characterized the defect as RPI 
deficiency (see Fig. 5) [6]. Until now, only one single diagnosed case of RPI deficiency 
has been described, making it one of the rarest diseases [16].  Because of these 
biochemical findings, the full-length RPIA cDNA was sequenced, and the authors found 
two different mutations, a single base-pair deletion (c.540delG) and a nucleotide 
substitution (c.182C>T), inherited from the mother and the father, respectively. The 
deletion causes a frameshift change with asparagine 181, leading to a premature 
termination of RPI protein translation, with a stop codon 17 amino acids downstream 
(p.N181fsX17). The missense mutation, c.182C>T, leads to the substitution of an 
alanine by a valine at codon 61 (p.A61V) [6].  
These mutations were not found in 220 control chromosomes of individuals of 
Northern Europe descent, indicating that those mutations are not likely to represent 
polymorphisms, but instead are pathogenic mutations. The truncated RPI protein 
encoded by the frameshift allele was not detected by Western blot, indicating that this 
protein is not expressed or is rapidly degraded. RPI concentrations in both lymphoblasts 
and fibroblasts of the patient showed a marked decline. These results were confirmed by 
quantitative mass spectrometry and a decline of around 30% in RPI levels was 
measured in the lymphoblasts of the patient, when compared to controls. Reinforcing 
these data, qPCR demonstrated that RPIA mRNA levels were strongly reduced in 
patient’s cells, around 40% in lymphoblasts and about 1% in fibroblasts, when 
compared to controls. A cell type-dependency was demonstrated, having been reported 
an enzyme activity of 30% in lymphoblasts and an activity bellow the assay’s detection 
limit in fibroblasts [16]. 
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Fig. 5. Schematic presentation of the pentose phosphate pathway in a ribose-5-phosphate 
isomerase (RPI) deficiency situation. 1) ribulose-5-phosphate epimerase, 2) transketolase, 3) 
transaldolase, 4) D-ribulose reductase, 5) D-arabitol dehydrogenase; 6) xylulokinase; 7) 
NAD(P)-independent ribitol dehydrogenase, 8) D-ribose reductase, 9) ribokinase. Little is 
known about mammalian pentitols formation. The dotted arrows represent presumed reactions, 
based in reactions occurring in microorganisms. Adapted from [6]. 
 
 
1.4.  Transaldolase (TALDO; E.C.2.2.1.2) 
TALDO is the second and rate limiting-enzyme of the non-oxidative branch of 
the PPP, catalyzing the reversible transfer of a three-carbon keto unit, corresponding to 
dihydroxyacetone (DHA), from sedoheptulose-7-phosphate (S7P) to glyceraldehyde-3-
phosphate (G3P) generating erythrose-4-phosphate (E4P) and fructose-6-phosphate 
(F6P) [2]. The TALDO1 gene (ID 6888) is located in the short arm of chromosome 11 
(11p15.4-p15.5 region) [17], and is highly conserved in most organisms. Humans 
possess a single gene for transaldolase [18], and until now no isoforms of TALDO are 
known. Mutations in this gene cause TALDO deficiency (OMIM #606003).  
The first description of a TALDO deficient patient was made by Verhoeven and 
co-workers in 2001 [7]. The patient was the first child of healthy, consanguineous 
Turkish parents. The patient presented low birth weight, mild bleeding problems and 
underwent, soon after birth, a surgical correction of aortic coarctation. Within several 
months, this patient developed liver cirrhosis and hepatosplenomegaly. She was 
diagnosed at the age of 10 years. At this age she presented thrombocytopenia, 
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hepatosplenomegaly, enlarged clitoris, and mildly increased coagulation times. Her 
neurological examinations showed normal results [7].  
In 2005, Verhoeven and co-workers [19] described the second patient with 
TALDO deficiency. The patient was the first of dizygotic female twins delivered by 
emergency at 36 weeks’ gestation. The parents were of Turkish origin (as the first case 
reported), and also consanguineous. Clinical symptoms in the neonatal period were 
related to severe liver failure (severe coagulopathy, low serum protein, elevated blood 
ammonia and hypoglycemia), generalized oedema, and this patient also featured 
moderate muscular hypotonia and dysmorphic signs (down-slanting palpebral fissures, 
low-set ears and increased intermamillary distance). Karyotype analysis demonstrated 
XX/XO mosaicism. The patient died at day 18 due to bradycardic heart failure. 
Remarkably, both patients showed transaminases and γ-glutmayltransferase levels 
within the reference range [19]. 
In 2006, Valayannopoulos and co-workers [20] described four patients from the 
same family. The parents were first cousins from Turkish origin. The couple had no 
healthy children. The four patients shared the same biochemical and molecular defect. 
They had hydrops fetalis and congenital multiorgan involvement. The major clinical 
signs described were: dysmorphic features, liver dysfunction with elevated 
aminotransferase levels and low albumin, hepatosplenomegaly, thrombocytopenia, 
hemolytic anemia (with schistocytes), renal involvement and heart problems [20]. 
Neurological examination showed normal results for all surviving patients [7, 19, 20].  
In 2007, Fung and co-workers [21] described a boy of a consanguineous 
Pakistan couple, with intrauterine growth retardation (IUGR) in the antenatal period; 
and hypoglycemia, thrombocytopenia, hepatosplenomegaly and deranged liver function 
and coagulation in the post-natal period. The patient developed failure to thrive, 
transient hypoglycemia and persistently mild thrombocytopenia [21].  
In 2008, Wamelink and co-workers [22] described a new TALDO deficient 
patient. The patient was the fourth child of consanguineous parents of Arabic ethnicity. 
The patient was born with hepatosplenomegaly and developed jaundice and 
thrombocytopenia. He had to be ventilated at day 9 because of poor respiratory effort. 
The patient developed cirrhosis but had no inflammatory infiltrate. Until now, this is the 
only TALDO deficient patient that has been described with  rickets and deafness [22].  
In 2009, Tylki-Szymanska and co-workers [23] described two cases of TALDO 
deficient patients of Polish origin. The patients were siblings of a healthy 
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consanguineous couple. Both patients presented hemolytic anemia and 
hypoproteinemia, hepatosplenomegaly (with mildly elevated serum transaminases in the 
first child and normal levels in the younger brother), thrombocytopenia and 
haemorrhagic diathesis with skin bleeding [23].  
In 2011, Balasubramaniam and co-workers [24] described the first TALDO 
deficient patient born from a nonconsanguineous couple of Chinese ethnicity. He 
presented at birth with hydrops fetalis and hypoalbuminemia. At the age of 2.5 months a 
splenomegaly (with normal liver and kidney function and blood parameters) with febrile 
illness was noted. Shortly after this febrile episode he was readmitted with seizures, 
jaundice, discrete dysmorphic features (cutis laxa), hepatosplenomegaly (with mildly 
elevated transaminases, bilirrubinemia and raised alkaline phosphatase), 
thrombocytopenia and Coombs negative hemolytic anemia. The patient died at the age 
of 4.5 months with flavobacterium sepsis and multiorgan failure [24].  
In 2013, Eyaid and co-workers [25] described twelve new cases of TALDO 
deficient patients from six Saudi consanguineous families. All patients shared clinical 
signs, being the principal findings IUGR, dysmorphic features, cardiac defects, 
hepatosplenomegaly, anemia and thrombocytopenia. As the authors followed part of the 
patients along childhood, it permitted to track the natural history of the disease over a 
larger number of years. The authors described that dysmorphic features (e.g. anti-
mongoloid slant, low set ears, cutis laxa) tend to disappear after the infancy, being more 
recognizable in the neonatal period. The bleeding tendency and liver involvement 
follows a more irregular course. The liver involvement was not always progressive and 
its severity was variable even within different members of the same family. None of 
these twelve patients presented hemolytic anemia, in contrast to the previously 
described patients, and all presented cardiac problems [25].  
All twenty-three patients described so far [7, 19–25] have the same sugars’ and 
polyols’ profile: elevated urinary concentrations of arabitol, ribitol, erythritol and 
sedoheptulose (see Fig. 6), and normal CSF profile. All patients, but the patients 
described by Tylki-Szymanska and co-workers and Fung and co-workers, presented 
elevated levels of D-arabitol, ribitol and erythritol in plasma. One can deduce that these 
patients would show the same plasmatic pattern of these compounds (i.e. elevated levels 
of D-arabitol, ribitol and erythritol) if plasma samples would have been analyzed. 
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Fig. 6. Schematic presentation of the pentose phosphate pathway in a transaldolase (TALDO) 
deficiency situation. 1) ribulose-5-phosphate epimerase, 2) ribose-5-phosphate isomerase, 3) 
transketolase, 4) xylulokinase, 5) D-arabitol dehydrogenase; 6) ribokinase, 7) D-ribose 
reductase. The dotted arrows represent presumed reactions, based in reactions occurring in 
microorganisms. Adapted from [26] 
 
Until now, the mutations found in TALDO deficient patients were: i) the 
homozygous deletion of three residues (corresponding to nucleotides 511-513) of the 
human TALDO1 cDNA, leading to the deletion of the amino acid serine at position 171 
(p.Ser171del) [15, 17]; ii) the homozygous missense mutation c.575G>A leading to the 
substitution of the amino acid arginine by a histidine at position 192 (p.Arg192His) 
[19]; iii) the homozygous missense mutation c.574C>T leading to the substitution of the 
amino acid arginine by a cysteine at position 192 (p.Arg192Cys) [9]; iv) the 
homozygous single base pair deletion (c.793delC) leading to a frameshift with 
premature truncation (p.Gln265ArgfsX56) [25]; and v) two heterozygous missense 
mutations: a) a deletion of 3 nucleotides in exon 7 (c.895_897delAAC), leading to the 
deletion of an asparagine at position 299 (p.Asn299del), inherited from the father; and 
b) a missense mutation c.931G>A in exon 7, leading to the substitution of the amino 
acid glycine by arginine at position 311 (p.Gly311Arg), inherited from the mother of the 
patient [24]. 
The deletion of three base pairs (c.511_513delTCC) is responsible for the 
production of a TALDO enzyme with no activity. Northern-blot analysis showed 
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normal TALDOΔ511-513 mRNA levels but Western-blot analysis showed no 
TALDOΔS171 protein in fibroblasts and lymphoblasts of the patient. The gene is 
transcribed and translated in vitro, but TALDOΔS171 has no detectable activity. The 
deletion of Ser171 resulted in conformational changes affecting the correct protein 
folding, leading to: 1) aggregation of misfolded protein, 2) dominance of the mutant 
protein leading to loss of wild-type activity, and 3) loss of function due to degradation 
of the mutant protein [27].  
Arginine 192 has been proposed to be part of the catalytic site of the enzyme. 
This region is highly conserved, as are the amino acids asparagine at position 299 and 
glycine at position 311 [28]. This, and the fact that in 210 control alleles none had a 
mutation in this region, indicates that those missense mutations p.Arg192His, 
p.Arg192Cys, and the p.Asn299del mutation, are pathogenic [22]. Table 1 summarizes 
the clinical and molecular features of all patients described until now. 
 
Table 1. Clinical and molecular features of the 23 TALDO deficient patients diagnosed to date. 
 
Clinical Features Cases reported
b
 
Consanguinity 22/23 
Hepatosplenomegaly 22/23 
Anemia 21/23 
Thrombocytopenia 21/23 
Cardiac problems 20/23 
Liver dysfunction 18/23 
Dysmorphia 17/23 
Wrinkly skin 16/23 
Neonatal edema 7/23 
Renal abnormalities 7/23 
Premature death 6/23 
Respiratory dysfunction 3/23 
Developmental delay  2/23
a
 
 
 
Molecular Features  
 
c.793delC (p.Gln265ArgfsX56) homozygous 12/23 
c.511_513delTCC (p.Ser171del) homozygous 5/23 
c.575G>A (p.Arg192His) homozygous 4/23 
c.574C>T (p.Arg192Cys) homozygous 1/23 
c.931G>A (p.Gly311Arg)/c.895_897delAAC (p.Asn299del) 
compound heterozygous 
1/23 
 
a Sensor neural deafness in one patient and initial mild delay with later catch-up in the other  
b Verhoeven 2001, Verhoeven 2005, Valayannopoulos 2006, Fung 2007, Wamelink 2008, Tylki-
Szymanska 2009, Balasubramaniam 2011 and Eyaid W, 2013 
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1.5.  Xylulose reductase (XR; E.C.1.1.1.10) 
L-xylulosuria or Essential Pentosuria (OMIM #608347) was firstly appointed as 
an inborn error of metabolism, with no apparent clinical consequences, in 1908 by Sir 
Archibald Garrod in his fourth Croonian Lecture [29]. The disease is characterized by 
high excretion of L-xylulose in the urine (1 to 4 g of the pentose per day) [30]. The 
disorder had been first described in 1892 by Salkowski and Jastrowitz [31], but it was 
only with the work of Levene and La Forge [32], in 1914, that the sugar excreted in 
such high concentrations was established as being xylulose [32]. In 1930, Greenwald 
characterized it as the enantiomorph D-xylulose [33]. However, in the same year, he 
wrote a correction letter to the same review stating that the sugar was indeed L(+)-
xylulose and not the previous D-xylulose [34]. The metabolic defect in essential 
pentosuria is at the level of xylulose reductase, an important enzyme of the glucoronic 
acid oxidation pathway, responsible for the conversion of L-xylulose to L-xylitol [30]. 
The condition was described in 1936, by Lasker and co-workers, as an inherited 
autosomal recessive characteristic [35] almost limited to persons of the Ashkenazi 
Jewish ancestry. The first reported case of a non-Hebrew patient with pentosuria was 
done by Barnes and Bloomberg in 1953, where they described the condition in two 
Lebanese sisters with no known Jewish ancestry [36]. After this case report, Politzer 
and Fleishmann in 1962 studied 127 members of a Lebanese family and found 10 cases 
of pentosuria. Nevertheless, due to the fact that not all samples of the ten affected 
members gave positive results at all times (the study lasted for four years), the authors 
postulated that the inheritance could be considered as dominant with poor penetrance 
[37]. It was also in 1962 that Khachadurian described twelve cases of pentosuria in 
three highly inbred Lebanese families, establishing, once and for all, the inheritance of 
pentosuria as having a Mendelian recessive pattern [38]. 
By ion-exchange chromatography of red cells’ L-xylulose reductase, Lane and 
co-workers [39] showed in 1984 that the enzyme existed in two isoforms, a minor and a 
major. The authors also showed that the pentosuric patients lacked the major isozyme, 
the isoform responsible for the conversion of the bulk of L-xylulose to xylitol in the 
glucoronic acid pathway, thus leading to the accumulation and excretion of high 
amounts of L-xylulose in urine (Fig. 7). The major and minor isoforms were postulated 
to be encoded by two separate genes, since normal individuals and pentosuric patients 
had similar amounts of the minor isozyme [39]. 
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Fig. 7. Schematic presentation of the glucoronic acid pathway and its link to the PPP. 1) 
Phosphoglucomutase,  2) UDP-Glucose pyrophosphorylase, 3) UDP-Glucose dehydrogenase, 4) 
UDP-Glucuronidase; 5) Glucuronate reductase, 6) L-Gulonate 3-dehydrogenase, 7) 
Decarboxylase, 8) Xylitol dehydrogenase, 9) D-Xylulokinase. Adapted from [40]. 
 
 
In 2002, Nakagawa and co-workers [41] characterized a ubiquitous enzyme that 
was highly expressed in liver and kidney, with a NADPH-linked reductase activity for 
α-dicarbonyl compounds and responsible for the conversion between L-xylulose and 
xylitol. Due to its activity, the enzyme was designated as dicarbonyl/L-xylulose 
reductase (DCXR), belonging to the short-chain dehydrogenase/reductase (SDH) 
superfamily [41].  
The DCXR gene (ID 51181) is located in the long arm of chromosome 17 
(17q25.3 region). The active protein is a homotetramer, with each subunit consisting of 
244 amino acid residues. Xylulose reductases (XRs) are highly conserved in organisms. 
The amino acid sequences of human, mouse, rat, guinea pig, and hamster share very 
high identities (83–99%) [42]. Pierce and co-workers [43] studied the DCXR gene in 
members of fifteen previously described pentosuric families, and found that the most 
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prevalent mutation was a single base-pair deletion, DCXR c.583ΔC, inducing a 
frameshift that led to a premature stop codon six residues downstream (p.His195fs6X). 
This mutation was found in homozygosity in six probands. Furthermore, six children of 
deceased probands were also carriers for this mutation. Another mutation altering the 
splice donor site of intron 1, DCXR c.52+1G>A, was also found in homozygosity in one 
proband and in heterozygosity in combination with the previous mutation (c.52+1G>A 
and c.583ΔC) in two other patients [43].  
The c.583ΔC mutation leads to a protein lacking more than 50 C-terminal amino 
acids, translating in a non-functional protein, once the C-terminal domain is responsible 
for the interactions between the monomers [42]. The DCXR c.52+1G>A mutation leads 
to mutant DCXR alternative transcripts. No DCXR protein was detectable in pentosuric 
patients with both genotypes, and heterozygous individuals had DCXR protein levels 
substantially lower than controls [43]. 
Essential pentosuria did not seem to have deleterious health or lifespan effects in 
patients and it was considered a benign condition. Furthermore, because the first 
biochemical tests used were not specific and gave raise to misleading diagnosis of 
diabetes, the screening for this condition was abandoned. The last update of the number 
of cases with established essential pentosuria (ca. 200) was reported, in 1958, by Eugen 
Knox [44]. 
 
 
1.6.  L-Arabinosuria 
L-Arabinosuria is a benign condition, marked by the excretion of high amounts 
of L-arabinose and L-arabitol in urine, plasma and CSF, after ingestion of fruit. The 
proposed enzyme defect is thought to be in L-arabitol dehydrogenase (E.C.1.1.1.12), 
although this has not yet been proven [45]. In 2002, Onkenhout and co-workers [45] 
described the only known case of L-arabinosuria, a sixteen-months-old girl of 
Egyptian/Dutch origin (non-consanguineous parents). The patient presented delayed 
motor development and facial dysmorphism (macrocephaly, palatoschizis and skeletal 
abnormalities). The mental development seemed to be normal at that time (although 
difficult to assess), and she was on a regular diet. No liver or kidney malfunctions were 
present. At the age of four years, her mental development was evaluated and considered 
normal (she was sociable and spoke Dutch and Arabic). All tests (plasma amino acids, 
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lactate, pyruvate, very-long-chain fatty acids and sialotransferrine isoelectric focusing, 
as well as urinary oligosaccharides, mucopolysaccharides and (free) sialic acid) showed 
normal results, except for reducing sugars in urine, although normal glucose levels were 
found. Galactose was high, but clinical background excluded galactosemia. Urinary 
sugars’ and polyols’ profiling by GC-MS was performed, and showed high excretion of 
arabitol (see Fig. 8), and a slightly increased excretion of fructose and xylose in urine 
(xylitol was in the normal range). Increased levels of arabitol and arabinose were also 
found in patient’s plasma and CSF. Urinary organic acids showed a large unknown 
peak, later identified as arabinoic acid (-lactone). When the patient had fruit removed 
from her diet, the excretion of arabinose normalized in one week, and in a six-week 
interval, urine, plasma and CSF presented normal levels of arabitol and arabinose. 
Although the treatment is based on a fruit-free diet, prolonged intake of L-arabinose 
food sources does not seem to have deleterious effects in human health [45]. 
 
 
Fig. 8. Human pentose inter-conversion suggested by Onkenhout et al., explaining the 
formation of L-arabinoic acid (-lactone), D-arabitol and L-arabitol. L-arabitol metabolism seems 
more likely to occur via L-xylulose than through L-ribulose. Adapted from [45]. 
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1.7.  The PPP and tumor cells’ metabolism 
Since the 1920s it is known that tumor cells display increased rates of glucose 
metabolism compared with normal tissues. Normal cells mainly produce energy from 
mitochondrial oxidative phosphorylation, whereas tumor cells mainly rely on 
fermentation to produce the energy needed, even in the presence of oxygen [46]. This 
phenomenon is denominated as the Warburg effect or aerobic glycolysis. In 1926, 
Warburg and co-workers demonstrated that about 66% of the glucose consumption, in 
tumor slices, was through fermentation, and the remainder through respiration despite 
the availability of oxygen [46]. The same authors also showed that in the time needed 
for a cancer tissue to metabolize 1 molecule of glucose by oxidative phosphorylation 
(yielding 36 ATP molecules), 12 more glucose molecules were converted to 24 lactic 
acid molecules, in normoxic conditions, by the so called aerobic glycolysis (yielding a 
total of 60 ATP molecules) [47]. The oxidative phosphorylation persists at the same 
time as aerobic glycolysis in the vast majority of tumors, if not all, continuing to supply 
energy necessary for housekeeping functions and biosynthetic reactions [41, 42]. For 
most mammalian cells metabolism, the major catabolic molecules are glucose and 
glutamine, being responsible for supplying carbon, nitrogen, free energy, and reducing 
equivalents required to cell growth and division [50]. So, if all glucose molecules were 
to be catabolized to CO2 by the oxidative phosphorylation to produce ATP, all the other 
needs of a growing cell (e.g. acetyl-CoA to produce fatty acids, glycolytic intermediates 
for nonessential amino acids to produce proteins, and ribose for nucleotides) would not 
be supplied. In 2007, using 
13
C Nuclear Magnetic Resonance (NMR) spectroscopy, 
DeBerardinis and co-workers [51] showed that more than 90% of total glucose 
metabolism was spent in the production of lactate and alanine, and 60% of total 
glutamine utilization was also used in the production of these compounds. Very 
importantly, a by-product of glutaminolysis, i.e. glutamine conversion to lactate by the 
action of malate dehydrogenase (malic enzyme; ME), is NADPH [51]. Also lactate 
production involving the enzyme lactate dehydrogenase (LDH) produces NADPH [50]. 
These NADPH molecules can supply other anabolic processes such as fatty acid 
synthesis and, together with ribose-5-phosphate (derived from the PPP), nucleotide 
synthesis [52]. The majority of acetyl-CoA is derived from glucose, and the majority of 
oxaloacetate (OOA) is derived from glutamine (accounting for a very important 
anaplerotic role in the TCA cycle) [51]. So, an inefficient usage of cellular resources, as 
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it appeared to be the Warburg effect, in which glucose produces lactate, ergo not 
exploiting the full capacity of oxidative metabolism to produce the so needed ATP, 
proved in fact to be an important pathway for faster incorporation of carbon into 
biomass, facilitating the huge requirements of rapid cell divisions [48, 49].  
Many metabolic routes regarding (de)regulation of cell metabolism in cancer 
cells, like fatty acids synthesis and mitochondrial respiration, are known and have been 
strongly studied, but in the purpose of this thesis, only aspects linked with the PPP have 
been highlighted and will be further discussed. Increased understanding of these 
complex networking pathways is needed to better characterize tumor cells metabolism, 
allowing the future development of new therapeutic targets in inhibition of cancer cells 
growth and proliferation. 
 
 
1.7.1. The PPP and tumor cells’ metabolism: p53 and G6PD 
 
The PPP is an important pathway for glucose catabolism and biosynthesis, 
playing a major role in providing key biosynthetic intermediates as NADPH and R5P. 
These intermediate metabolites are pivotal to cell proliferation, turning the PPP in an 
attractive metabolic route of target in tumor cells [53]. Recent studies have 
demonstrated that G6PD is overexpressed in certain tumor types (gastric, colorectal [54] 
and kidney tumors [55]). Furthermore, G6PD has been shown to be negatively regulated 
by wild-type but not mutant p53 [56]. p53 is a known tumor suppressor responsible for 
cell cycle arrest, DNA repair and apoptosis [57], and now an important role in 
modulating cancer cell metabolism is being “awarded” to p53.  
p53 is the most frequently mutated tumor suppressor gene in human cancers, and 
since its product binds to G6PD (inhibiting its activity), a mutated p53 will lead to a 
strong enhancement of PPP flux (~ 50%) by lack of G6PD activity regulation [56]. 
Studies performed by Jiang and co-workers [56] in p53
-/- 
human colon cancer HCT116 
cell line showed a strong increase in NADPH levels (~ 2 folds). The authors also 
studied the NADPH levels in heart, liver, kidney and lung tissues from p53
-/- 
mice, 
finding elevated levels compared to the corresponding tissues from p53
+/+ 
mice. 
Furthermore, p53 does not change the levels of G6PD transcript. It acts by disrupting 
the formation of the dimeric G6PD holoenzyme. G6PD needs NADP
+
 for the formation 
of the holoenzyme, and the diminished interaction between G6PD and NADP
+
 when 
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p53 binds, leads to disruption of the active dimeric G6PD formation (Fig. 9). These 
results are highlighted by the impaired interaction of G6PD and p53 in the presence of 
NADPH, in a dose-dependent manner [56]. 
 
 
1.7.2. The PPP and tumor cells’ metabolism: p53 and TIGAR 
 
TIGAR (TP53-induced glycolysis and apoptosis regulator) gene is located in the 
short arm of chromosome 12 (12p13-3 region) and contains six potential coding exons 
and two possible p53 binding sites (BS1, upstream of the first exon, and BS2 within the 
first intron). By microarray analysis, TIGAR gene was identified as inducible by p53 
[58]. Bensaad and co-workers [58] demonstrated that TIGAR protein shares similarities 
with proteins from the phosphoglycerate family (PGM), mainly with the biphosphatase 
domain of the different isoform products of the four genes (pfkfb 1-4) encoding the 
enzyme 6-phosphofructokinase 2/fructose-2,6-biphosphatase (PFK-2/FBPase-2). This is 
a bifunctional enzyme, with both kinase (NH2-terminal region of the enzyme) and 
phosphatase (COOH-terminal region) activities. TIGAR only shows similarities with 
the biphosphatase domain of PFK-2/FBPase-2, therefore only having the capability to 
dephosphorilate substrates [58].  
PFK-2/FBPase-2 regulates the synthesis (PFK-2; E.C.2.7.1.105) and 
degradation (FBPase-2; E.C.3.1.3.46) of intracellular fructose-2,6-biphosphate (Fru-
2,6-P2). This compound is a potent allosteric effector of 6-phosphofructokinase 1   
(PFK-1), stimulating glycolysis and inhibiting gluconeogenesis. TIGAR, through the 
dephosphorylation of Fru-2,6-P2, inhibits PFK-1 leading to accumulation of fructose-6-
phosphate (F6P). F6P is isomerized to glucose-6-phosphate (G6P) by phosphoglucose 
isomerase and G6P is diverted to the PPP (Fig. 9). The shift of G6P to the PPP leads to 
increased production of NADPH and R5P, important precursors of DNA biosynthesis 
and repair, also lowering apoptosis due to increased generation of reduced glutathione 
(GSH) and removal of reactive oxygen species (ROS) [58].  
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1.7.3. The PPP and tumor cells’ metabolism: The transketolase family 
 
Transketolase (TKT; E.C.2.2.1.1) is the first enzyme of the non-oxidative 
branch of the PPP and, together with transaldolase, links the oxidative branch of the 
PPP with glycolysis. TKT is an ubiquitous homodimeric enzyme [59], responsible for 
the reversible transfer of two-carbon units (1,2-dihydroxyethyl) in two major reactions: 
(i) conversion of Xu5P and R5P to S7P and G3P, and (ii) conversion of  Xu5P and E4P 
to F6P and G3P [2]. The TKT gene (ID 7086) is located in the short arm of chromosome 
3 (3p14.3 region) [60]. 
TKT is a thiamine diphosphate (ThDP, the active derivative of vitamin B1) and 
Ca
2+
 ion dependent enzyme [33, 34], presenting high degree of sequence similarities in 
different species [59]. 
The human genome encodes two related TKT proteins, TKTL1 and TKTL2 
(transketolase-like 1 and 2 protein) [63]. TKTL1 and TKTL2 share a sequence identity 
at the amino acid level of 61% and 66% compared to TKT, respectively. Not much is 
known about the biochemical properties of TKTL1 and TKTL2, and until now there are 
no reports on enzymatic or cellular functions of TKTL2 enzyme, and little is known 
about TKTL1 [59]. TKTL1 mRNA and protein levels, but not TKTL2 and TKT, are 
overexpressed in a wide variety of solid cancers and have been associated with 
transformation to a more malignant phenotype in different carcinoma entities [55]. This 
overexpression is connected to poor patient survival [64]. The enhancement of both 
oxidative and non-oxidative branch of the PPP in proliferating cells, due to huge needs 
in energy, amino acids, fatty acids, nucleotides and NADPH, explains the 
overexpression of TKTL1 (Fig. 9). Zhang and co-workers [65] showed that TKTL1 
accounts for approximately 50% of total transketolase content (TKT, TKTL1 and 
TKTL2), and that the use of TKTL1 RNA interference (RNAi-mediated suppression) 
leads to inhibition of more than 50% of total transketolase activity [65]. TKT plays an 
important role in recruiting glucose and synthesizing ribose, accounting for more than 
85% of newly synthesized ribose in cancer cells [66]. Boros and co-workers [66] also 
described that the usage of oxythiamine, an inhibitor of TKT, leads to decrease in the 
synthesis of nucleic acids and a huge reduction in cell volume and proliferation [66]. 
Taking all these data together, inhibiting TKTL1 or TKT activity can become a 
promising therapeutic target in future cancer therapy.  
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Fig. 9. Key components and intermediates of the pentose phosphate pathway (PPP). DNA 
damage can activate ATM, leading to Hsp27 phosphorylation that in turn will lead to the 
activation of G6PD. p53, an important tumor suppressor, regulates the PPP activity, by either 
disrupting the formation of the active dimeric G6PD; or by activating the TIGAR protein, which 
will inhibit glycolysis, leading to accumulation of fructose-6-phosphate (F6P), shifting the 
metabolism of G6P to the PPP. TKTL1 protein overexpression leads to enhancement of the 
PPP, being responsible for the production of newly synthesized ribose in cancer cells. Scheme 
adapted from [53]. 
 
 
1.7.4. The PPP and tumor cells’ metabolism: ATM 
 
Ataxia telangiectasia (A-T) is a rare autosomal recessive disorder, characterized 
by progressive neuronal degeneration, oculomotor apraxia, telangiectasias of the 
conjunctivae, immunodeficiency, frequent infections, radiosensitivity and an increased 
risk for malignancy, particularly leukemia and lymphoma [38, 39].  
The human A-T disease results from null mutations in the ATM gene, which 
encodes the protein kinase ATM (ataxia-telangiectasia mutated). ATM is rapidly 
activated when cells are exposed to DNA double-strand breaks (DSBs), a highly 
cytotoxic DNA lesion [38, 40]. The absence of ATM leads to impairment of DSBs 
repair [68]. ATM is responsible for the phosphorylation of numerous proteins involved 
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in cell cycle checkpoint control, apoptotic responses and DNA repair [69]. Moreover, an 
important role in the PPP metabolism has been ascribed to ATM. It has been described 
that ATM activates the p38-MK2 pathway, which is responsible for phosphorylation of 
the small heat shock protein Hsp27 upon DNA damage [70]. In 2011, Consentino and 
co-workers [68] described the relation between ATM, Hsp27 and G6PD. Although the 
mechanisms explaining the affinity of Hsp27 for G6PD through ATM induction are not 
well established, Hsp27 was described as regulator of G6PD activity in a non-
transcriptional manner. ATM induces G6PD activity by increasing the affinity of Hsp27 
for G6PD (Fig. 9). This regulation leads to an activation of the PPP, being of utmost 
importance in the increasing need of the dNTPs pool which allows DNA repair and 
NADPH production, pivotal for control of the redox metabolism [68]. 
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1. Introduction 
 
Sugars’ and polyols’ profiling in biological samples, such as urine, plasma and 
CSF, has become an invaluable tool in the assessment of the recently described 
diseases, RPI and TALDO deficiency, which affect the PPP. Intermediate sugars’ and 
polyols’ pattern found in patients carrying these diseases seem to be pathognomonic or, 
at least, highly predictive of the type of blockage in the PPP. Furthermore, the role of 
the PPP in several pathologies, such as liver and cancer diseases, has become very 
recently, subject of intensive study and the intermediate sugars and polyols of the PPP 
started to be  regarded  as possible  predictive biomarkers of the referred pathologies or, 
even, of their progress. Assessment to those metabolites is not part of the general 
metabolic screening.   
 The analysis of those metabolites has been addressed by specific analytical 
chromatographic methods such as: HPLC, GC-FID, GC-MS and more recently by 
LC/MS or LC-MS/MS. The qualitative and quantitative analysis of those metabolites 
can  be quite complicated due the similarity of compounds structure, weight and charge 
and also due to the huge difference, often seen,  among metabolites’ concentration in the 
same sample [1]. The optimization of the pre-analytical and analytical conditions is 
crucial for the precision of the qualitative and quantitative analysis. 
We were interested in setting-up a method able to analyze simultaneously sugars 
and polyols allowing, in a single run, an informative profile of the PPP intermediate 
metabolites. Therefore, a GC-FID method was developed based on the previous method 
published by Jansen and co-workers [1]. Minor modifications were introduced and all 
the analytical process was validated after the optimization of the analytical conditions. 
Moreover, the analysis by GC-MS was also accomplished having in mind the possibility 
of its input on the qualitative analysis. Furthermore, laboratory reference values for 
adult urinary sugars and polyols were established. 
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2. Material 
 
2.1. Standards 
 
The monosaccharides – Arabinose, Ribose, Xylose, Glucose, Galactose, 
Fructose and Fucose –, the disaccharides – Lactose, Maltose, Sucrose, Cellobiose and 
Melibiose –, the polyols – Threitol, Erythritol, Xylitol, Ribitol, Myo-inositol and 
Mannitol – as well as the internal standards (IS) – Mannoheptulose (IS-1) and Trehalose 
(IS-3) – were obtained from Sigma-Aldrich Co (St. Louis, MO USA). Perseitol (IS-2) 
was kindly supplied by Dr. Mirjam Wamelink from VU University Medical Center, 
Amsterdam, The Netherlands. Sugars’ and polyols’ main features are summarized in 
Table 1. 
 
2.2. Reagents 
 
The derivatization reagent Trimethylsilyl N-trimethylsilylacetamidate in 
chlorotrimethylsilane (BSA + TMCS + TMSI, 3:2:3), also known as Tri-Sil-TBT, and 
n-hexane CHROMASOLV
®
 for HPLC were purchased from Sigma-Aldrich Co (St. 
Louis, MO USA). Hydrochloric acid fuming 37%, methanol p.a. and butanol p.a. were 
obtained from Merck Darmstadt, FRG. 
 
2.3 - Biological Samples  
 
2.3.1. Controls  
 
2.3.1.1. Urine samples 
 
For the assessment of control sugars’ and polyols’ chromatographic profiles and 
reference values, a random urine sample from 16 volunteers (9 female, 7 male; ages 23-
50 yrs), healthy adults, all members of laboratory`s staff, was collected in the same day.  
All the samples were well homogenized and a pool was built by the mixture of equal 
volume of each urine sample. The created pool was divided in 1.5 mL aliquots, 
immediately frozen and kept at -20 
º
C until analysis. 
 
GC analysis of sugars and polyols: optimization of a GC-FID and a GC-MS method 
41 
 
Table 1. Sugars’ and polyols’ properties: name and purity degree, chemical formula, molecular weight, 
chemical abstracts service (CAS) number, original reference from manufacturer and chemical structure. 
 
Sugar / Polyol,  
purity 
Chemical 
Formula 
MW  
(g/mol) 
CAS- 
Number 
Ref. 
Chemical 
Structure 
      
D-(-)-Arabinose,  
≥ 98% 
C5H10O5 150.10 10323-20-3 A6085 
 
D-(+)-Arabitol, 
≥ 99% 
C5H12O5 152.15 488-82-4 A3381 
 
D-(+)-Cellobiose,  
≥  98% 
C12H22O11 342.30 528-50-7 C7252 
 
Meso-erythritol,  
≥ 99% 
C4H10O4 122.12 149-32-6 E7500 
 
D-(-)-Fructose,  
≥ 99% 
C6H12O6 180.16 57-48-7 F0127 
 
D-(+)-Fucose,  
≥ 98% 
C6H12O5 164.16 3615-37-0 F8150 
 
Galactitol, 
 ≥ 99% 
C6H14O6 182.17 608-66-2 D0256 
 
D-(+)-Galactose,  
≥ 99% 
C6H12O6 180.16 59-23-4 G0750 
 
D-(+)-Glucose,  
≥ 99.5% 
C6H12O6 180.16 50-99-7 G8270 
 
Myo-inositol,  
≥ 99% 
C6H12O6 180.16 87-89-8 I5125 
 
Lactose, Ph Eur,  
anhydrous 
C12H22O11 342.30 63-42-3 17814 
 
D-(+)-Maltose monohydrate, 
 ≥ 99% 
C12H22O11 . H2O 360.31 6363-53-7 M9171 
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Table 1 (cont.). Sugars’ and polyols’ properties: name and purity degree, chemical formula, molecular 
weight, chemical abstracts service (CAS) number, original reference from manufacturer and chemical 
structure. 
Sugar / Polyol,  
purity 
Chemical 
Formula 
MW  
(g/mol) 
CAS- 
Number 
Ref. 
Chemical 
Structure 
      
D-Mannitol, 
 ≥ 98% 
C6H14O6 182.17 69-65-8 M4125 
 
D-Mannoheptulose,  
≥ 99% 
C7H14O7 210.18 3615-44-9 97318 
 
D-(+)-Melibiose,  
≥ 99% 
C12H22O11 342.30 585-99-9 63630 
 
Perseitol,  
≥ 97% 
C7H16O7 
212.20 527-06-0 P8295 
 
Ribitol,  
≥ 99% 
C5H12O5 152.15 488-81-3 A5502 
 
D-(-)-Ribose,  
≥ 99% 
C5H10O5 150.13 50-69-1 R7500 
 
D-Sorbitol,  
≥ 99% 
C6H14O6 182.17 50-70-4 240850 
 
Sucrose, 
 ≥ 99.5% 
C12H22O11 342.30 57-50-1 S9378 
 
D-(+)-Trehalose dihydrate,  
≥ 99% 
C12H22O11 . 2H2O 378.33 6138-23-4 T9531 
 
D-Threitol,  
≥ 99% 
C4H10O4 122.12 2418-52-2 377619 
 
Xylitol,  
≥ 99% 
C5H12O5 152.15 87-99-0 X3375 
 
D-(+)-Xylose,  
≥ 99% 
C5H10O5 150.13 58-86-6 X1500 
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2.3.1.2. Plasma samples 
 
To test the efficacy of the chromatographic method for the analysis of plasma 
samples, the laboratory pool of plasmas was built and used as the method’s internal 
control. Moreover, plasma samples from patients with the established diagnosis of 
galactosemia, under dietetic control, were as well analyzed to test the chromatographic 
method’s ability to evaluate galactitol. 
 
3. Methods 
 
3.1. Standard Solutions 
 
Individual stock solutions for all the monosaccharides, disaccharides and polyols 
tested, as well as the compounds used as internal standards, were prepared in distilled 
water (Milli-Q, Millipore Corporation, Bedford, Ma EUA). These stock solutions (see 
Table 2 for details) were aliquoted in 1.5 mL microtubes and kept at – 20 ºC until 
further need. These individual stock solutions were used in the preparation of all the 
working solutions used in this study. 
 
Table 2. Individual stock solutions of sugars and polyols. 
 
Sugar / Polyol 
Stock Solution  
(mM) 
Sugar / Polyol 
Stock Solution 
(mM) 
    
Threitol 100 Mannitol 100 
Erythritol 100 Sorbitol 100 
Arabinose 100 Galactitol 100 
Ribose 100 Mannoheptulose (IS-1) 100 
Fucose 100 Myo-inositol 100 
Xylose 10 Perseitol (IS-2) 20 
Xylitol 100 Sucrose 100 
Arabitol 30 Lactose 100 
Ribitol 100 Maltose  100 
Fructose 100 Cellobiose 10 
Galactose 100 Trehalose (IS-3) 100 
Glucose 100 Melibiose 100 
    
 
IS: Internal Standard 
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3.2. Sample preparation 
 
Due to the fact that sugars and polyols do not contain functional groups allowing 
their direct selective isolation from biological materials, as already mentioned by Jansen 
et al., the sample`s pre-purification procedure is based on the removal of the other polar 
compounds (such as organic acids, amino acids and urea), after trimethylsilylation of 
the dry residue, by acidic hydrolysis and organic solvent extraction (see below) [1]. 
 
3.2.1. Urine samples 
 
 Urine aliquots were defrosted, at room temperature, homogenized by vortex spin 
(VXR basic Vibrax model, from IKA
®
, Staufen, Germany) and pH was verified using 
pH paper strips and adjusted, if necessary, to pH 5-7 with hydrochloric acid (0.1 mol/L). 
After pH adjustment, the urines were centrifuged (Eppendorf centrifuge 5810R, from 
Eppendorf AG, Hamburg, Germany) at 4000 rpm for 2 min at 24 ºC. The supernatant 
was collected and used for further extraction and derivatization. An aliquot was used for 
the measurement of creatinine (Creat) by the Jaffe method on a routine clinical 
chemistry analyzer (Pentra C200, from HORIBA ABX SAS, Montpellier, France). 
The amount of urine to be used was determined by the creatinine value. Two 
different approaches were used along this study: a) the urine volume was fixed for 
established ranges of creatinine (GC-MS analysis), as referred in Table 3 or b) it was 
calculated using formula A (GC-FID analysis), displayed below. 
 
Table 3. Volume of urine to be processed according to 
creatinine range. 
 
Creatinine (mM) Urine Volume (µL) 
 
< 1.0 
 
200 
  
1.0 – 5.0 100 
 
> 5.0 
 
50 
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Formula A: 
V = 1 / (X*Creat) 
 
V = volume of urine; X = 2, when Creat is lower than 1 mmol/L; the age of the 
individual is between 0-3 months and/or the individual displays a severe presence of 
oligosaccharides through the strip test; X = 1, in the absence of all the previous 
conditions. The maximum volume of urine that can be used is 500 µL. 
 
The urine sample, which volume was calculated as described, was then 
supplemented with 100 µL of a mixture of the internal standards (IS-1, IS-2 and IS-3, at 
200 µM, 200 µM and 100 µM, respectively). The sample was then evaporated, at 60 ºC, 
under a gentle stream of nitrogen, to dryness. For further information see protocol in 
Annex 1. 
 
3.2.2. Blood samples 
 
Blood samples, were collected in the presence of an anticoagulant agent (EDTA 
or Heparin). The plasma was separated by centrifugation for 10 min at 2000 rpm at 
room temperature. Plasma (500 µL) was supplemented with 100 µL of the IS mixture 
solution and it was deproteinized through the addition  of  2 mL of methanol, left for   
30 min at -20 ºC. After centrifugation (3000 rpm for 10 min, at 24 ºC) the supernatant 
was transferred to a glass vial and extracted with 4 mL of hexane. After centrifugation 
(3000 rpm for 2 min, at 24 ºC) the methanol layer was evaporated to dryness as 
previously described. See Annex 2 for protocol.  
 
3.2.3. Calibrators 
 
The calibrators were included in each batch of samples. They were prepared at a 
final concentration of 125 µM and 250 µM, from the individual stock solutions 
previously prepared (see Table 2 for details), aliquoted and kept at -20 ºC. For analysis, 
the aliquots were defrosted and to 100 µL of each working solution 100 µL of the IS 
mixture solution was added. The dry residue was obtained as described above. 
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3.2.4. Derivatization: sugars and polyols trimethylsilylether derivatives 
 
 The selective isolation of sugars and polyols from a biological matrix is quite 
difficult and time consuming. The biological samples pre-purification was achieved 
taking into consideration the stability of the sugars and polyols trimethylsilylether 
derivatives towards hydrolysis. The trimethylsilylation of the dried residues followed by 
reaction with aqueous hydrochloric acid solution leads to the hydrolysis of the formed 
trimethylesters and trimethylsilylated amines which are no further extractable by the 
organic solvent. Therefore, we follow the derivatization method described by Jansen et 
al.. To the obtained dry residue (urine, plasma or aqueous working solutions) the 
derivatization reagent, Tri-sil-TBT (300 µL), was added, vigorously shaken and 
incubated at 100 ºC for 30 min.  After cooling to room temperature, 1 mL of water 
(milli-Q) was added, vigorously shaken, followed by 1 mL of hexane, shaken for 2 min 
in the vortex, and then centrifuged for 2 min at 4000 rpm. The hexane layer was 
collected and washed with 1 mL of 0.1 mol/L hydrochloric acid aqueous solution. After 
centrifugation, at 4000 rpm for 2 min, the hexane layer was collected, transferred to a 
glass vial and a drop of bis(trimethylsilyl)trifluoroacetamide (BSTFA) was added to 
assure that the anomeric hydroxyl group of our compounds is trimethylsilylated. The 
hexane layer was then dried, at room temperature, under a gentle stream of nitrogen. 
The dry residue was re-dissolved with 100 µL of hexane. The vials were capped and 
stored at 4 ºC, until further analysis. See Annex 3 for protocol. 
 
3.3. High Performance Gas Chromatography (GC) 
 
3.3.1. Gas chromatography-flame ionization detector (GC-FID) system 
 
Gas chromatography was performed using an Agilent Technologies’ 7890A 
model, equipped with an autosampler G4513A model (also from Agilent Technologies) 
and interfaced with an Agilent ChemStation data system.  
 The column used was a CP SIL 5 CB, 25 m x 0.25 mm (I.D.) x 0.39 mm (UD), 
df = 0.12 µm, (Agilent Technologies), which is a fused-silica capillary column, 
containing 100 % dimethylpolysiloxane phase. Gas flow rate (helium) was 0.5 mL/min 
and detector and injector temperatures were 300 ºC and 275 ºC, respectively. The oven 
program was as follow: start point temperature 110 ºC, increased by 1.5 ºC/min to     
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156 ºC and then 4 ºC/min from 156 ºC to 265 ºC followed by 10 ºC/min from 265 ºC to 
295 ºC, and hold at 295 ºC for 20 min. The total run time was approximately 80 min per 
sample. In order to optimize the chromatographic resolution, several approaches to 
establish the best oven program conditions were tested (for further information see 
Annex 4). Fig. 1 represents the selected temperature program adopted.  
Samples (2 µL) were injected in the split mode (1/15) using the automatic 
injector. The syringe was washed before each sample injection with 3 rinses of hexane 
and immediately after with 3 rinses of butanol. 
 
Summary of chromatographic conditions: 
 
Injector: split / splitless 
Injector Temperature: 275 ºC 
Split flow: 17 mL / min 
Carrier gas: Helium (Air Liquide, LDA); flow rate of 0.5 mL / min 
Make-up and detector gas: Air, Hydrogen and Nitrogen (Air liquide, LDA) 
Capillary column:  WCOT fused silica 
Stationary phase: CP Sil 5 CB 
    Length: 25 m 
    Internal diameter: 0.25 mm 
    Film thickness: 0.12 µm 
Detector: Flame ionization detector (FID); temperature: 300 ºC 
 
 
 
Fig. 1. Oven temperature program: starting at 110 ºC rising to 295 ºC in four steps, 
with a total run time of approximately 80 min/sample. 
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3.3.2. Gas chromatography-mass spectrometry (GC-MS) system 
 
Gas chromatography with mass spectrometry detection was performed using a 
GC-2010 model, equipped with an autosampler AOC-20i model (both from Shimadzu 
Co, Japan) and interfaced with a GC-MS solution 2.53 data system, from Lab. 
Solutions, Shimadzu Co, Japan.  
The column used was a CP SIL 19 CB, 25 m x 0.25 mm (I.D.), df = 0.2 µm 
(Agilent Technologies), which is a fused-silica capillary column bonded with 14% 
cyanopropyl-phenyl / 86% dimethylpolysiloxane. Gas flow rate (helium) was kept at  
0.6 mL/min and the split ratio was 1:15. The mass spectrometer parameters were as 
follows: source temperature, 250 ºC; collision energy, 70 eV and injector temperature, 
275 ºC. The oven program used was the one previously established for the GC-FID 
system (see Fig. 1). 
 The sample volume injected was 0.5 µL and the syringe cleaning program was 
the same as described above for the GC-FID system (see 3.3.1). 
 
Summary of chromatographic conditions: 
 
Injector: split / splitless 
Injector Temperature: 275ºC 
Purge flow: 3.0 mL / min 
Split ratio: 1:15 
Carrier gas: Helium (flow rate: 0.6 mL / min) (Air liquide, LDA) 
 
Capillary column:  WCOT fused silica 
Stationary phase: CP Sil 19 CB 
   Length: 25 m 
   Internal diameter: 0.25 mm 
   Film thickness: 0.2 µm 
 
Mass spectrometer parameters:  
Ion Source Temperature: 250 ºC 
    Interface Temperature: 230 ºC 
    Ionization energy: 70 eV 
    Acquisition mode: Scan 
    Event time: 0.5 sec 
    Start m/z: 40.00 
    End m/z: 700.00 
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4. Results 
 
4.1. Qualitative analysis 
 
4.1.1. GC-FID Profiles 
 
A representative GC-FID profile of the 21 sugars and polyols, as 
trimethylsilylether derivatives, of an aqueous standard solution, obtained under the 
adopted chromatographic conditions is shown in Fig. 2. All tested compounds are well 
separated, displaying a base line resolution, except xylose (peak 1) and fucose (peak 2) 
which co-elute. Different oven temperature programs as well as mobile phase flow rates 
were tested (see Annex 4). In spite of all the modifications, the resolution between 
xylose (peak 1) and fucose (peak 2) was not improved. Therefore the previous 
chromatographic conditions based on the work of Jansen et al., with some modifications 
(see Fig. 1), were the ones adopted along this work. 
 
 4.1.2. Retention Time (RT) and Relative Retention Time (RRT) 
 
Taking into consideration that the majority of the trimethylsilyl-sugars give rise 
to a second derivative peak (peak 2), it is of the upmost importance that each laboratory, 
under the adopted working conditions, establish their proper list of retention time (RT) 
for the tested compounds. RT and relative retention time (RRT) of pure compounds are 
crucial chromatographic parameters for the subsequent qualitative analysis of unknown 
samples. RT is a characteristic of each compound, under given chromatographic 
conditions, therefore being the fingerprint of the compound.  
Due to the complexity of the chromatographic profile, a total of 33 peaks (peak 1 
plus peak 2 in most sugars) corresponding to 24 distinct sugars and polyols were 
analyzed. Different standard working solutions were prepared containing all selected 
sugars and/or polyols, at a final concentration of 125 µM. The carbohydrates in each 
working solution were selected in order to avoid chromatographic co-elution. This 
precaution allowed the correct identification of the analytes and their corresponding RT. 
The composition of each standard solution is displayed in Table 4.  
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Fig. 2. A GC-FID chromatographic profile of all 21 tested sugars and polyols plus the three IS, 
as trimethylsilylether derivatives. All analytes are present in a concentration of 125 µM, except 
IS-1, IS-2 and IS-3, in a concentration of 200 µM, 200 µM and 100 µM respectively. 
 
 
Peak   Peak   Peak  
 C4   C6   C7 
1 Threitol  7 Fucose peak 1
*
  21 Mannoheptulose (IS-1) 
2 Erythritol  8 Fucose peak 2  23 Perseitol (IS-2) 
    13 Fructose     
 C5  14 Galactose peak 1   Disaccharides 
3 Arabinose peak 1  15 Glucose peak 1
*
  24 Lactose peak 1 
4 Arabinose peak 2
*
  16 Galactose peak 2
*
  25 Sacarose 
5 Ribose peak 1  17 Mannitol  26 Maltose peak 1
*
 
6 Ribose peak 2
*
  18 Sorbitol  27 Cellobiose peak 1 
8 Xylose peak 1  19 Galactitol  28 Maltose peak 2 
9 Xylitol  20 Glucose peak 2  29 Trehalose (IS-3) 
10 Arabitol  22 Myo-inositol  30 Lactose peak 2
*
 
11 Ribitol      31 Cellobiose peak 2
*
 
12 Xylose peak 2
*
     32 Melibiose peak 1 
        33 Melibiose peak 2
*
 
        
 
*
Peak used to calculate sugars concentration. 
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Table 4. Composition of standard solutions used for the determination of the retention time. All 
carbohydrates were in a concentration of 125 µM. 
 
Standard Solutions Sugar / Polyol 
  
1 Threitol; Arabinose; Mannitol and Galactitol 
2 Erythritol; Ribose; Xylose and Sorbitol 
3 Fucose; Xylitol; Arabitol; Ribitol and Fructose 
4 Galactose; Maltose; Sacarose and Melibiose 
5 
 
Glucose; Myo-inositol; Lactose and Cellobiose 
 
 
To calculate the RRT of each sugar and polyol, a mixture of the 21 tested 
compounds (125 µM each) plus the three IS was used. The RRT of each compound was 
determined using one of the three IS, as indicated in Table 5. The choice was based in 
structure similarity and/or chromatographic proximity. 
 
Table 5. List of tested compounds and indication of the IS to be used in calculation of the RRT 
 
Sugar / Polyol IS Sugar / Polyol IS 
     
Threitol 2 Sorbitol 2 
Erythritol 2 Galactitol 2 
Arabinose peak 1 1 Glucose peak 2 1 
Arabinose peak 2 1 Mannoheptulose (IS-1) - 
Ribose peak 1 1 Myo-inositol 2 
Ribose peak 2 1 Perseitol (IS-2) - 
Fucose peak 1 1 (2)
a
 Lactose peak 1 3 
Xylose peak 1/ Fucose peak 2  1/2
b
  Sacarose 3 
Xylitol 2 Maltose peak 1 3 
Arabitol 2 Cellobiose peak 1 3 
Ribitol 2 Maltose peak 2 3 
Xylose peak 2 1 Trehalose (IS-3) - 
Fructose 1 Lactose peak 2 3 
Galactose peak 1 1 Cellobiose peak 2 3 
Glucose peak 1 1 (2)
a 
Melibiose peak 1 3 
Galactose peak 2 1 (2)
a 
Melibiose peak 2 3 
Mannitol 2   
    
 
a 
Internal standards used for quantitative analysis. 
b
 Xylose peak 1 and Fucose peak 2 co-elute.  
IS: Internal standard used for RRT calculation (1- mannoheptulose, 2- perseitol and 3-trehalose). 
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Nevertheless, the compound RRT relative to each of the three ISs were 
calculated. The RRT of all the tested sugars and polyols in aqueous standard solutions, 
analyzed as trimethylsilylether derivatives under the adopted chromatographic 
conditions, are shown in Table 6. Excellent reproducibility for all the RRT was observed 
regardless of the IS used.  
 
Table 6.  Reproducibility of the RRT of the sugars and polyols trimethylsilylethers derivatives in the 
aqueous standard solutions.  
  RRT (IS-1) RRT (IS-2) RRT (IS-3) 
Sugar / Polyol Peak # Mean 
a 
(n = 10)  
%RSD 
Mean 
a 
(n = 10) 
%RSD 
Mean 
a 
(n = 10)   
%RSD 
Threitol 1 0.423 0.03 0.388 0.08 0.323 0.08 
Erythritol 2 0.435 0.03 0.398 0.08 0.331 0.09 
Arabinose peak 1 3 0.567 0.02 0.519 0.07 0.432 0.08 
Arabinose peak 2 4 0.602 0.02 0.551 0.06 0.458 0.06 
Ribose peak 1 5 0.614 0.02 0.562 0.07 0.468 0.07 
Ribose peak 2 6 0.628 0.02 0.575 0.07 0.478 0.07 
Fucose peak 1 7 0.637 0.02 0.583 0.06 0.485 0.07 
Xylose peak 1/Fucose peak 2 b 8 0.683 0.02 0.625 0.06 0.520 0.06 
Xylitol 9 0.709 0.02 0.650 0.05 0.542 0.91 
Arabitol 10 0.727 0.01 0.666 0.01 0.554 0.01 
Ribitol 11 0.734 0.01 0.672 0.04 0.559 0.04 
Xylose peak 2 12 0.753 0.01 0.690 0.04 0.574 0.04 
Fructose 13 0.819 0.01 0.750 0.02 0.624 0.03 
Galactose peak 1 14 0.855 0.00 0.783 0.02 0.651 0.02 
Glucose peak 1 15 0.876 0.00 0.802 0.02 0.667 0.02 
Galactose peak 2 16 0.889 0.01 0.814 0.02 0.677 0.02 
Mannitol 17 0.917 0.01 0.840 0.02 0.698 0.02 
Sorbitol 18 0.921 0.01 0.843 0.02 0.702 0.02 
Galactitol 19 0.924 0.01 0.846 0.02 0.704 0.02 
Glucose peak 2 20 0.947 0.01 0.867 0.04 0.721 0.04 
Mannoheptulose (IS-1) 21 1.000 0.00 0.916 0.00 0.762 0.01 
Myo-inositol 22 1.009 0.01 0.924 0.01 0.769 0.01 
Perseitol (IS-2) 23 1.092 0.00 1.000 0.00 0.832 0.01 
Lactose peak 1 24 1.272 0.00 1.165 0.01 0.969 0.01 
Sacarose 25 1.275 0.01 1.167 0.01 0.971 0.01 
Maltose peak 1 26 1.289 0.00 1.181 0.01 0.982 0.01 
Cellobiose peak 1 27 1.292 0.01 1.183 0.01 0.984 0.00 
Maltose peak 2 28 1.308 0.01 1.197 0.01 0.996 0.01 
Trehalose (IS-3) 29 1.313 0.01 1.202 0.01 1.000 0.00 
Lactose peak 2 30 1.322 0.00 1.211 0.01 1.007 0.00 
Cellobiose peak 2 31 1.331 0.00 1.219 0.01 1.014 0.00 
Melibiose peak 1 32 1.351 0.01 1.237 0.01 1.029 0.00 
Melibiose peak 2 33 1.357 0.01 1.242 0.01 1.033 0.00 
a RRT represents the mean of 10 independent analyses of the standard solution.  
b Xylose peak 1 and Fucose peak 2 co-elute 
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4.1.3. Area of Peak 1/Peak 2 Ratio: another parameter in qualitative analysis 
 
As already referred, the majority of the sugar trimethylsilylether derivatives give 
rise, at least, to two peaks (peak 1 and 2) with distinct chromatographic characteristics. 
From a quantitative point of view, it is a disadvantage either due to loss of sensitivity 
and/or quality of the results. On the other hand, from a qualitative point of view, it may 
help the identification, since the ratio of peak 1 area relative to the one of peak 2 is a 
characteristic of the compound. In Table 7, the peak 1 versus peak 2 area ratio of the 
tested sugars, in aqueous standard solutions, is presented. According to Mirjam 
Wamelink (personal communication) the range to be used for further identification of 
peaks in unknown samples should be defined as the mean ± 3 STD, due to the 
variability of peak 1/peak 2 area ratio, which in part is determined by the efficiency of 
the derivatization procedure in each moment. Nevertheless, the calculated % RSD (8.0 – 
14.6) is still acceptable for these type of compounds, the formed trimethylsilylether 
derivatives and the analytical method. 
 
 
 
Table 7. Sugars peak 1 / peak 2 area ratio after analysis of aqueous standard solutions under the 
adopted chromatographic conditions. 
 
 Peak 1 Area / Peak 2 Area 
Sugar 
Mean
a
  
(n=26) 
STD % RSD Mean ± 3STD 
     
Arabinose 0.555 0.044 8.0 0.422 - 0.687 
Ribose 2.071 0.193 9.3 1.491 - 2.652 
Galactose 0.549 0.062 11.2 0.364 - 0.734 
Glucose 0.745 0.109 14.6 0.419 - 1.071 
Lactose 0.683 0.096 14.0 0.396 - 0.970 
Maltose 0.675 0.092 13.6 0.399 - 0.952 
Cellobiose 0.782 0.081 10.3 0.539 - 1.024 
Melibiose 0.608 0.063 10.4 0.418 - 0.797 
     
 
  a
Mean of 26 independent experiments analysed along 1 month  
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4.1.4. Precision of the Qualitative Analysis 
 
In Fig. 3 the chromatograms of an aqueous standard solution (A), a pooled 
control sample respectively of urine (B) and plasma (C), of healthy adults, as well as 
that of a galactosemic patient plasma sample (D), under dietetic treatment, are 
displayed. As it can be observed, in all displayed profiles, the chromatographic 
resolution was not apparently affected by the biological matrix. The identification of the 
peaks was made through the peak RRT calculated versus the internal standards, as 
shown in Table 8. One additional tool, the peak 1/peak 2 area ratio, was used in the 
identification of the sugars. The calculated range, mean ± 3 STD, for peak 1/peak 2 area 
ratio, is displayed in Table 9. 
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Fig. 3. Chromatograms of: (A) aqueous standard solution; (B) pooled urine sample of healthy 
adults under free diet; (C) pooled plasma sample, used in the lab for the preparation of internal 
controls and (D) plasma sample of a Galactosemic patient, under diet restriction. The analysis 
conditions are the same as shown in Fig. 1. The peak numbers correspond to the ones displayed 
in Fig. 2. 
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Table 8.  Reproducibility of the Relative Retention Time (RRT) of the sugars and polyols 
trimethylsilylether derivatives in the pooled urine sample used as control (see 2.3). 
  
RRT 
a
 
  
Mannoheptulose  
(IS-1) 
Perseitol  
(IS-2) 
Trehalose  
(IS-3) 
Sugar / Polyol 
Peak 
# 
b
 
Mean 
(n= 23) 
% RSD 
Mean 
(n = 23) 
% RSD 
Mean 
(n = 23) 
% RSD 
        Threitol 1 0.423 0.04 0.387 0.09 0.322 0.09 
Erythritol 2 0.435 0.04 0.398 0.07 0.331 0.08 
Arabinose peak 1 3 0.567 0.04 0.519 0.08 0.432 0.09 
Arabinose peak 2 4 0.602 0.04 0.551 0.07 0.458 0.07 
Ribose peak 1 5 0.614 0.06 0.562 0.06 0.467 0.07 
Ribose peak 2 6 0.628 0.04 0.575 0.05 0.478 0.06 
Fucose peak 1 7 0.636 0.03 0.583 0.07 0.485 0.08 
Xylose peak 1/  
Fucose peak 2 
c
 
8 0.683 0.04 0.625 0.06 0.520 0.06 
Xylitol 9 0.709 0.03 0.649 0.05 0.540 0.06 
Arabitol 10 0.727 0.02 0.666 0.04 0.554 0.05 
Ribitol 11 0.734 0.03 0.672 0.04 0.559 0.05 
Xylose peak 2 12 0.753 0.03 0.690 0.04 0.574 0.05 
Fructose 13 0.819 0.03 0.750 0.03 0.624 0.04 
Galactose peak 1 14 0.855 0.01 0.783 0.02 0.651 0.02 
Glucose peak 1 15 0.876 0.01 0.802 0.02 0.667 0.02 
Galactose peak 2 16 0.889 0.01 0.814 0.02 0.677 0.02 
Mannitol 17 0.917 0.01 0.840 0.01 0.698 0.01 
Sorbitol 18 0.921 0.01 0.843 0.01 0.701 0.02 
Galactitol 19 0.924 0.01 0.846 0.01 0.704 0.02 
Glucose peak 2 20 0.947 0.01 0.868 0.01 0.722 0.01 
Mannoheptulose (IS-1) 21 1.000 0.00 0.916 0.00 0.762 0.01 
Myo-inositol 22 1.009 0.00 0.924 0.01 0.768 0.01 
Perseitol (IS-2) 23 1.092 0.00 1.000 0.00 0.832 0.01 
Lactose peak 1 24 1.272 0.00 1.164 0.01 0.969 0.01 
Sacarose 25 1.275 0.01 1.167 0.01 0.971 0.01 
Maltose peak 1 26 1.289 0.01 1.181 0.01 0.982 0.01 
Cellobiose peak 1 27 1.292 0.02 1.183 0.02 0.984 0.03 
Maltose peak 2 28 1.308 0.01 1.197 0.01 0.996 0.01 
Trehalose (IS-3) 29 1.313 0.01 1.202 0.01 1.000 0.00 
Lactose peak 2 30 1.323 0.01 1.211 0.01 1.007 0.01 
Cellobiose peak 2 31 1.331 0.01 1.219 0.01 1.014 0.01 
Melibiose peak 1 32 1.351 0.01 1.237 0.01 1.029 0.00 
Melibiose peak 2 33 1.357 0.01 1.242 0.01 1.033 0.00 
 
a 
RRT represents the mean of 23 independent analyses of the pooled urine control sample. 
 
b 
Peak number corresponding with those in Fig.2. 
c 
Xylose peak 1 and Fucose peak 2 co-elute. 
IS: Internal standard. 
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The reproducibility of the compounds RRT was excellent, despite the complexity 
of the urine matrix. The similarity of the RRTs of unknown compounds with the ones 
corresponding to the pure compounds clearly showed that the biological matrix did not 
interfere in the chromatographic characteristics of the compounds, therefore allowing 
their unequivocal identification. 
Table 9. Sugars’ peak 1 versus peak 2 area ratio after analysis of control pooled urine samples 
under the adopted chromatographic conditions. 
 
 
Peak 1 Area / Peak 2 Area 
Sugar Mean 
a
 (n=26) STD % RSD Mean ± 3 STD 
     
Arabinose 0.434 0.033 7.6 0.335 - 0.532 
Galactose 0.484 0.061 12.5 0.302 - 0.666 
Glucose 0.623 0.057 9.2 0.451 - 0.794 
Lactose 0.694 0.029 4.1 0.608 - 0.781 
Maltose 0.596 0.024 4.0 0.524 - 0.669 
Cellobiose 0.919 0.044 4.8 0.787 - 1.051 
Melibiose 0.511 0.016 3.1 0.463 - 0.558 
     
 
a
 Mean of 26 independent determinations of the pooled urine control sample. 
Ribose - not detected. 
 
The information given by the area of peak 1/peak 2 ratio shows that the range of 
reference is in accordance with that calculated for the pure compounds. Nevertheless, as 
it is established as a mean ± 3 STD, it turns to be less straightforward in its usefulness 
as an isolated parameter and, accordingly, must be used as a second tool of information, 
exclusively. However, when there is no match with the pure compound peak 1/peak 2 
area ratio, this parameter clearly rules out the identity of the compound in the unknown 
sample compared to the pure compound. The precision of the qualitative analysis was 
also tested through the analysis of urine samples from patients with established 
diagnosis of transaldolase (TALDO) deficiency, galactosemia, as well as from a 
diabetic patient with liver dysfunction. Samples were kindly supplied by Dr. Mirjam 
Wamelink from the VU University Medical Center, Amsterdam, The Netherlands. The 
chromatograms are shown in Fig. 4. These examples confirm the applicability of the 
present method to the biochemical diagnosis of carbohydrates metabolism defects. 
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Furthermore, the analysis of TALDO patient`s sample allowed the evaluation of the RT 
and RRT of sedoheptulose, a sugar which is not available in the market as a standard. 
 
 
 
Fig. 4. Chromatograms of urine samples of: (A) TALDO deficient patient; (B) Galactosemic 
patient (C) Diabetic patient (10 times diluted). The analysis conditions are the same as shown in 
Fig. 1. The peak numbers correspond to the ones displayed in Table 8 and Fig. 2. Peak 34 
corresponds to sedoheptulose. 
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4.1.5. GC-MS Profiles 
 
The analysis of the sugars and polyols, as trimethylsilyl derivatives, was also 
performed by GS-MS with the objective to evaluate if the mass spectra could be an 
additional tool for peak identification in unknown samples.  
A representative total ion chromatogram (TIC) of 21 sugars and polyols 
trimethylsilylether derivatives, plus the three internal standards, obtained using the 
previous established chromatographic conditions (see 3.3.2.), is shown in Fig. 5. The 
chromatographic resolution was not complete for all the tested compounds. Although, 
no co-elution between xylose peak 1 and fucose peak 2 is observed, maltose peak 1 and 
cellobiose peak 1, arabitol and ribitol, and sorbitol and galactose peak 2 show total co-
elution. A partial co-elution is also observed between the peak of sorbitol plus galactose 
peak 2 and galactitol, turning this chromatographic system unsuitable for the 
quantification of galactitol. Furthermore, and finally, in this chromatographic system, 
fructose displays two derivatives (peak 1 and peak 2). 
Two working solutions, as displayed in Table 10, were prepared taking into 
consideration the relative chromatographic position of the tested compounds, to avoid 
erroneous identification between flanking peaks. These working solutions were used to 
obtain the RT of the analytes and subsequently to calculate their RRT. 
 
Table 10.  Composition of working standard solutions  
 
Sugar / Polyol A [µM] B [µM] Sugar / Polyol A [µM] B [µM] 
       
Threitol - 125 Glucose 250 - 
Erythritol - 125 Mannitol 250 - 
Arabinose 250 - Sorbitol - 125 
Ribose 250 - Galactitol 250 - 
Fucose - 125 Myo-inositol 250 - 
Xylitol 250 - Sucrose 250 - 
Ribitol 250 - Lactose 250 - 
Xylose - 125 Maltose 250 - 
Fructose 250 - Melibiose - 125 
Galactose 250 - Cellobiose - 125 
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Fig. 5. GC-MS total ion chromatogram profile of 21 tested sugars and polyols plus the three IS, 
as trimethylsilylether derivatives. All analytes were in a concentration of 125 µM, except IS-1, 
IS-2 and IS-3, in a concentration of 200 µM, 200 µM and 100 µM, respectively. 
 
Peak 
 #   
Peak 
 #   
Peak 
 #  
 C4   C6   C7 
1 Threitol  6 Fucose peak 1  21 Mannoheptulose (IS-1) 
2 Erythritol  11 Fucose peak 2  23 Perseitol (IS-2) 
    13 Fructose peak 1     
 C5  14 Fructose peak 2   Disaccharides 
3 Arabinose peak 1  15 Galactose peak 1  24 Sacarose 
4 Ribose peak 1  16 Glucose peak 1  25 Lactose peak 1 
5 Arabinose peak 2  17 Mannitol
 
 26
 Maltose peak 1
 
7 Ribose peak 2  18
 Sorbitol
 
 26
 Cellobiose peak 1 
8 Xylitol  18
 Galactose peak 2  27 Maltose peak 2 
9 Xylose peak 1  19 Galactitol  28 Trehalose (IS-3) 
10 Arabitol  20 Glucose peak 2  29 Lactose peak 2 
10 Ribitol  22 Myo-inositol  30 Cellobiose peak 2 
12 Xylose peak 2     31 Melibiose peak 1 
      32 Melibiose peak 2 
        
 
IS: Internal standard 
 
The RRT of all tested compounds was calculated, for details see Table 11. The 
RRT of all 21 sugars and polyols trimethylsilyl derivatives analyzed by GC-MS, 
presented a % RSD < 0.6 %. The results confirm the excellent reproducibility of the 
gas-chromatographic system. 
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Table 11. Reproducibility of the RRT of the sugars and polyols trimethylsilylether derivatives in 
the aqueous standard solutions analyzed by GC-MS. 
 
Sugar / Polyol 
 
RRT 
a 
Peak  
#
 b 
Mannoheptulose 
(IS-1) 
Perseitol (IS-2) Trehalose (IS-3) 
Mean  
(n = 8) 
% RSD 
Mean 
(n = 8)  
% RSD 
Mean  
(n = 8) 
% RSD 
Threitol 1 0.372 0.010 0.339 0.040 0.274 0.050 
Erythritol 2 0.375 0.020 0.342 0.050 0.277 0.060 
Arabinose peak 1 3 0.547 0.030 0.499 0.020 0.404 0.030 
Ribose peak 1 4 0.597 0.030 0.544 0.030 0.441 0.020 
Arabinose peak 2 5 0.604 0.010 0.551 0.020 0.446 0.020 
Fucose peak 1 6 0.616 0.020 0.562 0.040 0.455 0.040 
Ribose peak 2 7 0.621 0.020 0.566 0.020 0.458 0.020 
Xylitol 8 0.651 0.030 0.594 0.020 0.481 0.020 
Xylose peak 1 9 0.665 0.030 0.607 0.030 0.491 0.030 
Arabitol 10
*
 0.667 0.020 0.609 0.030 0.493 0.030 
Ribitol 10
*
 0.668 0.020 0.609 0.030 0.493 0.030 
Fucose peak 2 11 0.686 0.030 0.626 0.030 0.507 0.040 
Xylose peak 2 12 0.750 0.020 0.684 0.020 0.554 0.030 
Fructose peak 1 13 0.785 0.020 0.716 0.020 0.580 0.020 
Fructose peak 2 14 0.799 0.020 0.729 0.020 0.590 0.020 
Galactose peak 1 15 0.852 0.010 0.777 0.010 0.629 0.010 
Glucose peak 1 16 0.876 0.010 0.798 0.010 0.646 0.010 
Mannitol 17 0.894 0.010 0.815 0.020 0.660 0.010 
Sorbitol 18
* 
0.901 0.030 0.821 0.030 0.665 0.020 
Galactose peak 2 18
* 
0.902 0.010 0.822 0.000 0.666 0.000 
Galactitol 19 0.905 0.010 0.825 0.030 0.668 0.030 
Glucose peak 2 20 0.960 0.010 0.875 0.000 0.709 0.010 
Mannoheptulose (IS-1) 21 1.000 0.000 0.912 0.000 0.738 0.010 
Myo-inositol 22 1.027 0.010 0.936 0.010 0.758 0.010 
Perseitol (IS-2) 23 1.097 0.000 1.000 0.000 0.810 0.010 
Sucrose 24 1.306 0.010 1.191 0.010 0.964 0.010 
Lactose peak 1 25 1.314 0.010 1.198 0.010 0.970 0.010 
Maltose peak 1 26
* 
1.329 0.000 1.212 0.010 0.981 0.000 
Cellobiose peak 1 26
* 
1.331 0.030 1.213 0.020 0.982 0.020 
Maltose peak 2 27 1.349 0.010 1.229 0.010 0.995 0.000 
Trehalose (IS-3) 28 1.355 0.010 1.235 0.010 1.000 0.000 
Lactose peak 2 29 1.373 0.010 1.251 0.010 1.013 0.010 
Cellobiose peak 2 30 1.377 0.030 1.256 0.020 1.017 0.020 
Melibiose peak 1 31 1.402 0.010 1.278 0.010 1.035 0.010 
Melibiose peak 2 32 1.408 0.030 1.283 0.020 1.039 0.020 
 
a 
Mean of 8 independent determinations 
b
 Peak number corresponding with those in Fig. 5. 
* 
Co-elution between Sorbitol and Galactose peak 2, and maltose peak 1 and cellobiose peak 1. 
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Following the same rationale, as for the analysis by GC-FID, the sugars peak 1 
versus peak 2 area ratio was also calculated. Results are shown in Table 12. As expected 
there is no match with the results previously calculated for GC-FID analysis, since this 
parameter is defined by the type of chromatographic system. Therefore, for each 
chromatographic system it is necessary to calculate peak 1/peak 2 area ratios to use this 
parameter in the qualitative analysis. 
 
Table 12. Sugars’ peak 1/peak 2 area ratio after analysis of the aqueous standard solutions 
under the adopted chromatographic conditions for GC-MS. 
 
 
Peak 1 Area / Peak 2 Area 
Sugars 
Mean 
(n=4) 
STD % RSD Mean ± 3STD 
     
Arabinose 0.732 0.020 2.8 0.670 - 0.793 
Ribose 3.940 0.147 3.7 3.498 - 4.382 
Fucose 0.521 0.016 3.2 0.472 - 0.570 
Xylose 0.710 0.097 13.7 0.419 - 1.002 
Fructose 0.153 0.010 6.7 0.122 - 0.184 
Glucose 0.849 0.052 6.1 0.693 - 1.006 
Lactose 0.701 0.041 5.9 0.577 - 0.824 
Maltose 0.551 0.049 9.0 0.403 - 0.700 
Cellobiose 0.869 0.080 9.2 0.630 - 1.108 
Melibiose 0.545 0.050 9.2 0.394 - 0.695 
      
a 
Mean of 4 independent analysis of the trimethylsilyl-sugars in the aqueous standard 
solutions 
 
Moreover, the mass spectrum of each of the tested compounds was established. 
In order to be ensured, for each tested compound, the unequivocal identification of the 
mass-to-charge ratio (m/z) of the most abundant ions, the pure tested compounds were 
analyzed one by one, in a scan detection mode. The characteristic m/z values of each 
carbohydrate are summarized in Table 13. The similarities of the m/z among the tested 
compounds ruled out the usefulness of the mass spectrum of the trimethylsilyl-sugars’ 
and –polyols’ derivatives as one unique tool in the identification of unknown 
compounds.  
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Table 13.  Summary of the most abundant ions m/z for the tested carbohydrates  
 
Sugar / Polyol m/z (mass-to-charge ratio) 
  
D-Arabinose peak 1 73, 217, 204, 191, 147, 45, 133 
D-Arabinose peak 2 73, 217, 204, 191, 147, 45, 133 
D-Arabitol 73, 217, 147, 103, 129, 205, 307, 189 
D-Cellobiose peak 1 73, 204, 191, 217, 147, 103, 129, 243, 361 
D-Cellobiose peak 2 73, 204, 191, 217, 147, 103, 129, 243, 361 
meso-Erythritol 73, 147, 217, 103, 117, 205, 189, 133, 204, 129 
D-Fructose peak 1 73, 204, 147, 217, 437, 45, 129, 103, 189, 292 
D-Fructose peak 2 73, 204, 147, 217, 437, 45, 129, 103, 189, 292 
D-Fucose peak 1 73, 204, 147, 191, 189, 205 
D-Fucose peak 2 73, 204, 191, 147, 189, 217 
Galactitol 73, 217, 147, 103, 205, 319, 129, 307, 117 
D-Galactose peak 1 73, 204, 191, 217, 147, 129, 45, 103 
D-Galactose peak 2 73, 204, 191, 217, 147, 129, 45, 103 
D-Glucose peak 1 73, 204, 191, 147, 217, 45, 129, 103 
D-Glucose peak 2 73, 204, 191, 147, 217, 45, 129, 103 
Myo-inositol 73, 217, 147, 305, 191, 318, 265, 204, 129, 103 
Lactose peak 1 73, 204, 191, 217, 147, 129, 103 
Lactose peak 2 73, 204, 191, 217, 147, 129, 103 
D-Maltose peak 1 73, 204, 191, 147, 217, 361, 103, 129 
D-Maltose peak 2 73, 204, 191, 147, 217, 361, 103, 129 
D-Mannitol 73, 147, 205, 319, 103, 217, 117, 129, 157, 307 
D-Mannoheptulose (IS-1) 204, 73, 147, 129, 217, 45, 103, 191, 117, 359 
D-Melibiose peak 1 73, 204, 44, 191, 147, 129, 217, 103 
D-Melibiose peak 2 73, 204, 44, 191, 147, 129, 217, 103 
Perseitol (IS-2) 73, 147, 217, 103, 205, 319, 129, 117, 191, 157 
Ribitol 73, 103, 217, 147, 129, 205, 319, 117, 189, 307 
D-Ribose peak 1 73, 217, 191, 204, 147 
D-Ribose peak 2 73, 217, 191, 204, 147 
D-Sorbitol 73, 147, 319, 217, 103, 205, 117, 129, 157 
Sucrose 73, 361, 217, 147, 103, 169, 129, 271, 437 
D-Trehalose (IS-3) 73, 361, 191, 147, 217, 103, 129, 204, 169, 271 
D-Threitol 73, 147, 217, 103, 117, 57, 189, 133 
Xylitol 73, 43, 217, 57, 103, 147, 129, 319, 307 
D-Xylose peak 1 73, 204, 147, 217, 191, 189, 205, 133 
D-Xylose peak 2 73, 204, 147, 217, 191, 189, 205, 133 
  
 
IS: Internal Standard 
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4.2.Quantitative analysis 
 
4.2.1. Linearity 
 
The linearity was studied for all the tested compounds, along this study, through 
the analysis of standards aqueous solutions at the following concentrations: 25, 50, 125 
and 250 µM for each analyte. All calibration curves displayed a coefficient of 
correlation (R
2
) > 0.99, except for threitol and erythritol (≥ 0.98) and for ribose (= 0.97). 
Table 14 summarizes the full results. Calibrations curves are shown in Annex 5. 
Table 14. Coefficient of linear correlation for the 21 sugars and polyols studied in aqueous 
solutions. Concentration range: 25-250 µM.  
 
Sugar / Polyol Linear Regression R
2
 
Threitol y = 0.0048 x 0.9801 
Erythritol y = 0.0049 x 0.9821 
Arabinose y = 0.0022 x 0.9975 
Ribose y = 0.0010 x 0.9700 
Fucose y = 0.0018 x 0.9994 
Xylitol y = 0.0033 x 0.9999 
Arabitol y = 0.0031 x 0.9962 
Ribitol y = 0.0034 x 0.9999 
Xylose y = 0.0026 x 0.9998 
Fructose y = 0.0041 x 0.9999 
Galactose y = 0.0022 x 0.9987 
Glucose y = 0.0017 x 0.9993 
Mannitol y = 0.0043 x 0.9997 
Sorbitol y = 0.0079 x 0.9995 
Galactitol y = 0.0041 x 0.9994 
Myo-inositol y = 0.0044 x 0.9992 
Lactose y = 0.0053 x 0.9999 
Sacarose y = 0.0098 x 0.9998 
Maltose y = 0.0031 x 0.9949 
Cellobiose y = 0.0049 x 0.9999 
Melibiose y = 0.0045 x 0.9998 
 
4.2.2. Intra-assay and inter-assay precision and recovery 
 
The results were obtained by making use of the internal standards indicated in 
Table 5. The quantification of the sugars was performed using the peak1 area or peak 2 
area as indicated in Figure 2. 
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For the inter-assay precision analysis, the pooled urine was analyzed along one 
month without and with supplementation, 125 µM or 250 µM, with different sugars and 
polyols. The results are summarized in Table 15.  
 
Table 15. Imprecision and recoveries of the sugars and polyols trimethylsilylether derivatives in 
the pooled urine control sample by GC-FID.  
 
Sugar 
 
Peak  
# 
a 
Intra-assay 
b 
(n= 6 ) 
Inter-assay
 c 
(n= 11) 
 
Recovery (%)
d
 
(n= 4 ) 
 
 
 
      
Threitol 1 7.7 (14.6 %) 6.6 (27.1 %) 72.8 (11.2 %) 
Erythritol 2 26.4 (12.9 %) 23.0 (26.2 %) 81.0 (11.1 %) 
Arabinose 4 15.9 (5.8 %) 14.2 (13.7 %) 105.6 (3.3 %) 
Ribose 6 n.d. n.d. n.p. 
Fucose 7 3.3 (7.5 %) 2.8 (14.8 %) 79.7 (4.1 %) 
Xylitol 9 4.9 (5.3 %) 4.6 (10.0 %) 81.5 (3.6 %) 
Arabitol 10 22.9 (4.0 %) 21.9 (8.0 %) n.p. 
Ribitol 11 6.5 (5.1 %) 5.9 (15.1 %) 100.5 (3.5 %) 
Xylose 12 2.4 (17.2 %) 2.3 (22.7 %) n.p. 
Fructose 13 11.9 (1.0 %) 11.8 (4.8 %) n.p. 
Glucose 15 28.3 (0.2 %) 24.8 (11.3 %) n.p. 
Galactose 16 17.5 (2.2 %) 16.8 (6.8 %) 103.0 (5.2 %) 
Mannitol 17 26.7 (3.2 %) 26.2 (4.0 %) 98.8 (2.3 %) 
Sorbitol 18 1.9 (8.2 %) 2.0 (5.3 %) 96.5 (1.8 %) 
Galactitol 19 3.8 (3.2 %) 3.6 (5.8 %) 95.2 (1.7 %) 
Myo-inositol 22 7.3 (1.8 %) 7.3 (3.8 %) 98.3 (1.6 %) 
Sacarose 25 7.0 (6.2 %) 6.6 (7.3 %) n.p. 
Maltose 28 n.d. n.d. 87.2 (6.5 %) 
Cellobiose 31 n.d. n.d. 95.1 (6.0 %) 
Lactose 30 15.0 (3.9 %) 14.3 (5.5 %) n.p. 
Melibiose 33 n.d. n.d. 94.1 (8.5 %) 
 
 
     
a
 Peak numbers corresponding with those in Fig. 2 and Table 5 
b
 Concentration (mmol/mol creatinine), mean (% RSD). 
c
 Concentration (mmol/mol creatinine), mean (% RSD). 
d
 Mean (% RSD). 
n.d. not detected; n.p. not performed. 
 
 
The intra-assay and the inter-assay variations range were 0.2 – 17.2% and       
4.8 - 27.1%, respectively. The highest variation was observed for the two first polyols – 
threitol and erythritol – mainly in the inter-assay. This variation may reflect the 
efficiency of the observed recovery, respectively 72.8% and 81.0%, which are among 
the lowest of the tested compounds. Clearly, when these two polyols are present at low 
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concentrations, the imprecision of their quantification must be considered. For all the 
other tested compounds, the recovery was in the range of 79.7 - 105.6%.  
 
4.2.3. Reference Values 
 
In Table 16, the reference values obtained with the optimized method and 
determined through the analysis of random urines collected from 16 adult healthy 
volunteers, under free diet and out of any medication, are compared with the ones 
reported by Jansen et al. and Wamelink et al. [1,2]. High similarity in the results was 
observed. 
 
Table 16.  Urinary concentrations (mmol/mol creatinine) of major sugars and polyols in a 
group of healthy adults. Comparison with published results by Jansen et al..  
 
Sugar / Polyol 
Peak 
# 
a
 
Mean 
(n = 16) 
Ref. Range 
b 
(20 – 30 yrs) 
Ref. Range 
c
 
(18-77 yrs) 
Ref. Range
d 
 (5-80 yrs) 
Threitol 1 9.3 2 - 32 4.8 - 34.3 0 - 35 
Erythritol 2 28.2 17 - 48 19.2 - 75.5 14 - 88 
Arabinose 4 18.3 9 - 30 8.2 - 36.7 
 
- 
 
Ribose 6 2.8 n.d. - 4 
 
- 
  
- 
 
Fucose 7 3.3 n.d. - 8 n.d. - 12.3 
 
- 
 
Xylitol 9 5.8 3 - 12 1.3 - 20.0 0 - 12 
Arabitol 10 26.1 18 - 45 10.2 - 43.9 6 - 60 
Ribitol 11 6.8 3 - 16 1.8 - 5.4 0 - 7 
Xylose 12 3.9 
 
- 
 
3.7 - 53.6 
 
- 
 
Fructose 13 38.5 5 - 97 4.6 - 57.0 
 
- 
 
Glucose 15 28.4 15 - 65 3.7 - 27.7 
 
- 
 
Galactose 16 17.8 2 - 40 n.d. - 21.7 
 
- 
 
Mannitol 17 13.5 8 - 114 3.1 - 60.5 2 - 28 
Sorbitol 18 4.4 1 - 34 2.3 - 26.3 0 - 15 
Galactitol 19 4.4 1 - 7 1.5 - 5.6 
 
- 
 
Myo-inositol 22 8.4 2 - 21 2.3 - 22.7 
 
- 
 
Sacarose 25 8.5 n.d. - 41 0.8 - 30.6 
 
- 
 
Maltose 26 1.2 n.d. - 2 
 
- 
  
- 
 
Lactose 30 15.7 2 - 26 1.3 - 7.4 
 
- 
 
Cellobiose 31 - 
 
- 
  
- 
  
- 
 
Melibiose 33 - 
 
- 
  
- 
  
- 
 
 
a
 Peak numbers corresponding with those in Fig. 2 and Table 5. 
b 
Reference values determined by the GC-FID method developed in the laboratory. 
c 
Reference values from Jansen et al. [1]. 
d 
Reference values from Wamelink et al. [2]. 
n.d., not detectable. 
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5. Discussion 
 
The profiling of sugars and polyols in body fluids regained an increased 
relevance with the recently discovery of new enzymatic defects in the non-oxidative 
branch of the PPP. Specific profiles of PPP intermediate metabolites were associated 
with distinct blockages and therefore started to be a useful tool in the screening of this 
group of pathologies. 
The analysis of sugars and polyols has been accomplished essentially by 
chromatographic methodologies, namely Liquid (LC) or Gas Chromatography (GC). 
HPLC analysis has been useful for the analysis of phosphate forms of intermediate 
sugars but it is quite time consuming for routine laboratory work. Recently, LC-MS/MS 
methods for the analysis of different sugar-phosphates [3, 4] and polyols in urine were 
developed [2]. GC with flame ionization detection or coupled to mass detection offers 
high chromatographic resolution as well as good sensitivity. A simple pre-purification 
sample procedure was proposed by Jansen and co-workers [1], therefore being suitable 
for screening purposes. 
 Based on the work of Jansen and co-workers, a GC- FID and GC-MS methods 
were optimized for the simultaneous analysis of sugars and polyols in body fluids. The 
selected chromatographic conditions allowed a resolution to the base line for the 
majority of the peaks of interest. Two parameters were used in the qualitative analysis, 
namely relative retention time (RRT) and the ratio of the areas of the two peaks (peak 1 
and 2) assigned to the corresponding sugar trimethylsilylether derivatives. The 
combination of these two parameters allowed a correct qualitative analysis of unknown 
samples in comparison with pure standards. As already highlighted the mass spectrum 
analysis did not add additional data in terms of unequivocal qualitative analysis but it 
allows to distinguish matrix interference from a true sugar or polyol. 
The reproducibility of the used parameters in the qualitative as well as the 
quantitative analysis was excellent as the agreement of our reference values for 
urinary`s sugars and polyols proves. In conclusion, the optimized method seems to be 
an useful tool for the study of the PPP, allowing not only to expand the screening 
program capability of the laboratory but to contribute to the exploration of the 
biochemistry determinants of the PPP which is far from being fully understood as well. 
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1. Introduction 
 
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease 
recognized in Europe and North America. The prevalence of NAFLD is estimated in   
20 – 30% in general population of Western countries [1, 2]. However, these estimations 
need to be confirmed by testing the significance of the risk factors identified by clinical 
series in the general population [3]. NAFLD was thought to be a benign condition, but 
is nowadays recognized as a major cause of liver-related morbidity and mortality [4]. In 
many cases, NAFLD is associated with obesity, hyper- or dyslipidemia, hyperglycemia, 
type II diabetes and insulin resistance [5-7]. NAFLD is currently defined as fat 
accumulation in the liver exceeding 5% to 10% of the weight of the liver [2]. NAFLD is 
an asymptomatic condition and the diagnosis is mostly made when liver alanine 
aminotransferase (ALT) and/or aspartate aminotransferase (AST) enzymes are elevated 
[5], or alternatively when hepatomegaly is detected in ultrasonography performed for 
another purpose, and without abnormal liver tests [6]. Non-alcoholic steatohepatitis 
(NASH) is the progressive form of NAFLD that carries a risk for development of 
fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) [3]. NAFLD is differentiated 
from alcoholic fatty liver disease (AFLD) by the alcohol intake. The distinction is based 
on the intake of ethanol under two standard drinks a day (140 g ethanol/week) for men, 
and one standard drink a day (70 g ethanol/week) for women. Liver biopsy is the only 
way to confirm the presence or absence of NASH in a NAFLD patient [6].  
Transketolase (TKT; E.C.2.2.1.1) and transaldolase (TALDO; E.C.2.2.1.2) are 
the key enzymes of the non-oxidative branch of the pentose phosphate pathway (PPP). 
TKT is the first enzyme, a thiamine diphosphate (ThDP, active vitamin B1) and Ca
2+
 
ion dependent enzyme [7], and TALDO is the second enzyme, a cofactor-less enzyme 
[8]. Together, these two enzymes create a reversible link between the oxidative branch 
of the PPP and glycolytic intermediates. The PPP activity is regulated according to the 
needs of the organism and the metabolic situation. If the PPP products are not needed, 
they are readily transformed into glycolytic intermediates and oxidized [7]. 
Since the description in 2001, by Verhoeven and co-workers [9], of the first 
patient with transaldolase deficiency, associated with liver cirrhosis and 
hepatosplenomegaly, in the first child of healthy, consanguineous Turkish parents [9], 
the non-oxidative branch of the PPP has regained notoriety, although the contribution to 
metabolism and cell survival remains poorly understood [8]. Since this first case, 
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twenty-two other patients have been described in the literature [10-16] and almost all 
patients presented with hepatosplenomegaly (22/23) and liver dysfunction of similar 
magnitude (18/23). 
In 2009 Hanczko and co-workers demonstrated that homozygote (Taldo1
-/-
) and 
heterozygote (Taldo1
+/-
) Taldo1 deficient mice presented increased rates of cirrhosis 
and that HCC was the leading cause of death, 17% and 46% respectively, when 
compared to Taldo1
+/+
 littermates. The authors also observed the formation of 
microvesicular and macrovesicular lipid droplets indicative of steatosis or non-alcoholic 
fatty liver disease, hepatocyte ballooning and inflammatory changes like non-alcoholic 
steatohepatitis [17].   
Taken together, the liver dysfunction, the recent cases of enzymatic defects in 
the PPP, namely transaldolase deficiency, and the findings described by Hanczko et al., 
this study was started with the main goal of understanding a putative link between the 
biochemical intermediate metabolites of the PPP and the hepatic dysfunction in patients 
with liver disease of unknown cause (NAFLD) or patients with hepatic dysfunction due 
to alcohol abuse (AFLD), in the presence or absence of inflammation, cirrhosis and 
HCC.  
In patients with liver dysfunction due to alcohol abuse, the evaluation of these 
PPP intermediate metabolites may allow the definition of new predictive biomarkers 
either of disease progression or of the effectiveness of the established treatment. 
 
 
2. Material 
To characterize the pattern of metabolites involved in the PPP of adult patients 
with NAFLD  and AFLD, a protocol was established between the Metabolism and 
Genetics group of iMed.UL, at Faculty of Pharmacy and the Hepatology Section of 
Internal Medicine Department at Santa Maria`s University Hospital, both from the 
University of Lisbon. The protocol was submitted and approved by the hospital ethical 
council and informed consents were obtained from all the participants in the study.  
Since the approval of the study (May 2012) until the present date, 14 patients 
with hepatic dysfunction (AFLD or NAFLD) were enrolled in the study. A random 
urine sample was collected when the patient visited the clinician for regular control. 
Eleven patients had AFLD, and all presented a cirrhotic liver (11/11). Among these, 
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patient 9 was diagnosed as having HCC, and along the course of this study, patient 12 
progressed also to HCC.  The remaining three patients had non-alcoholic steatohepatitis 
(NASH), and none presented a cirrhotic liver. Table 1 summarizes the main features of 
all fourteen patients enrolled in the study. 
 
 
3. Results and Discussion 
Patients (Table 1) were divided, as already mentioned, into two main groups 
according to the type of liver dysfunction: (i) NASH (Table 2) and (ii) AFLD (Table 3). 
NASH patients’ group is a more homogenous group than AFLD patients’ group. None 
of NASH patients developed cirrhosis and/or HCC. In contrast, the AFLD patients’ 
group is a more heterogeneous one, spanning from compensated to decompensated 
cirrhosis and progressing to HCC in two cases.  
The results of sugars and polyols for the NASH and AFLD groups are presented 
in Table 2 and Table 3, respectively. Table 3 summarizes all patients of the AFLD 
population, and as shown, patients 2, 4, 9 and 12 presented the highest levels of polyols. 
These data led us to subdivide the AFLD group into two subgroups: AFLDa (Table 4) 
and AFLDb (Table 5), with respectively minor and major alterations in polyols’ profile.  
Patients belonging to the NASH population showed no major abnormalities in 
their polyols’ profile. However, all the patients revealed increased (until 3 fold) ribitol 
levels, when compared with the reference values. Slight increased excretion of arabitol 
was detected in patients 3 and 5, and erythritol was slightly elevated in patient 5. In 
none of these patients sedoheptulose was observed.  
The mild alterations observed in glucose, galactose and galactitol excretion 
levels have no specific significance since these alterations are often observed in 
situations of liver disease and point out to some deregulation of the PPP non-oxidative 
branch. However, we must highlight that the number of patients studied so far is too 
small to allow any conclusion. 
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Table 2.  Urinary carbohydrates results (mmol/mol Creat) of NASH patients. Values 
presented in red are above the reference values. 
 
Sugar / Polyol P3 P5 P11 Reference Values 
a 
     
Threitol 15.0 12.9 9.9         5 - 34 
Erythritol 48.9 80.9 15.2       19 - 76 
Arabinose  17.3 22.5 14.4         8 - 37 
Ribose - 2.9 0.7      - 
Fucose 3.7 5.9 6.4     n.d. - 12 
Xylitol 16.7 14.2 6.8     n.d. - 20 
Arabitol 50.7 65.5 16.4       10 - 44 
Ribitol 6.3 15.8 11.0   n.d. - 5 
Xylose 3.9 7.2 2.5         4 - 54 
Fructose 26.7 3.8 -         5 - 57 
Glucose 47.1 109.3 206.4         4 - 28 
Galactose 5.0 24.5 40.5     n.d. - 22 
Mannitol 49.0 24.7 4.6         3 - 61 
Sorbitol 4.2 6.2 2.7         2 - 26 
Galactitol 9.7 5.2 6.7       2 - 6 
Sedoheptulose - - -       - 
Myo-inositol 106.8 54.7 75.7         2 - 23 
Sacarose 8.3 12.0 3.5    n.d. -31 
Maltose - 0.7 -       - 
Cellobiose - 0.3 -      - 
Lactose 12.5 17.5 5.4 n.d. -7 
Melibiose - - -      - 
     
 
a
 Reference values according to age group 
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Table 3. Urinary carbohydrates results (mmmol/mol Creat) of AFLD patients. Values presented in red are 
above the reference values. 
 
Sugar / Polyol P1 P2 P4 P6 P7 P8 P9 P10 P12 P13 P14 Ref. Val 
a
 
             
Threitol 13.8 88.6 6.9 10.2 15.1 15.1 55.0 26.7 47.2 6.3 31.7  5 – 34 
Erythritol 24.1 98.5 38.4 13.2 22.2 46.7 124.6 41.6 74.1 46.3 19.6    19 – 76 
Arabinose 33.2 32.1 18.1 10.1 12.6 25.1 37.6 16.8 20.3 10.6 11.0  8 – 37 
Ribose 5.3 2.0 - 5.7 1.1 - - - - 8.0 -         – 
Fucose 14.4 14.0 3.6 2.3 5.0 7.1 9.8 4.6 7.6 4.7 3.7  n.d. – 12 
Xylitol 60.2 42.3 549.2 12.7 17.0 22.4 29.5 17.1 26.9 7.5 15.1  n.d. – 20 
Arabitol 43.8 108.5 111.0 19.3 27.8 36.2 99.9 34.6 71.2 33.1 29.3    10 – 44 
Ribitol 18.1 35.5 90.7 9.3 5.9 12.8 29.1 8.3 25.4 7.4 7.8  n.d. – 5 
Xylose 23.1 73.3 9.7 2.7 1.1 17.0 51.7 5.4 8.9 3.2 90.5   4 – 54 
Fructose 4.3 114.9 6.0 46.7 42.9 38.8 - 38.2 46.9 20.2 1.0   5 – 57 
Glucose 67.5 52.4 305.3 31.3 416.0 69.2 91.1 27.0 59.8 48.7 26.7   4 – 28 
Galactose 5.6 6.7 4.6 3.8 3.2 1211.7 9.9 7.2 113.6 41.4 5.9  n.d. – 22 
Mannitol 13.7 264.9 63.7 84.1 16.9 1038.4 1387.1 73.1 42.7 957.3 11.2   3 – 61 
Sorbitol 8.2 93.3 29.6 2.9 6.6 9.7 25.1 2.4 13.3 1.8 2.9   2 – 26 
Galactitol 4.6 17.6 1.9 1.5 1.6 9.6 5.9 7.7 9.3 4.3 3.4      2 – 6 
Sedoheptulose - - - - - - - - - - - – 
Myo-inositol 16.4 20.2 28.9 3.7 21.8 23.0 11.7 11.1 13.5 9.1 3.9      2 – 23 
Sacarose 1.6 110.7 14.6 11.4 22.7 23.3 86.4 27.4 88.0 1.1 23.3  n.d. – 31 
Maltose - - - - - - - - - - 0.4 – 
Cellobiose - - - - - - - 0.4 - - 0.8 –  
Lactose 7.2 22.2 2.4 83.3 3.6 27.9 27.3 8.9 54.6 13.8 19.3  n.d. – 7 
Melibiose - - - 0.5 0.4 - 8.1 - 0.4 - 1.3 –  
             
 
a
 Reference values according to age group 
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As previously referred, patients of the AFLD group were divided into two 
subgroups, according to their polyols’ pattern. Patients of the AFLDa group (table 4) 
showed no major abnormalities in these compounds. However, one major finding is that 
all patients have elevated excretion of ribitol, ranging from slightly above the higher 
reference value until up to ~ 4 fold. Accordingly, ribitol elevation was a consistent 
finding throughout all patients enrolled in this study. The extremely high excretion of 
mannitol in patients 8 and 13 may be explained by the usage of this polyol, as a 
component of many drugs` excipients, due to its humectant properties and pleasant 
taste. These patients are under medication not only for their liver dysfunction, but also 
hypertension (patient 8), gastrointestinal problems and anxiety disorders (patient 13). 
 
Table 4. Urinary polyols results (mmol/mol Creat) of the AFLDa patients. Values presented in 
red are above the reference values. 
Polyol P1 P6 P7 P8 P10 P13 P14 Ref Val 
a
 
         
Threitol 13.8 10.2 15.1 15.1 26.7 6.3 31.7    5 – 34 
Erythritol 24.1 13.2 22.2 46.7 41.6 46.3 19.6   19 – 76 
Xylitol 60.2 12.7 17.0 22.4 17.1 7.5 15.1 n.d. – 20 
Arabitol 43.8 19.3 27.8 36.2 34.6 33.1 29.3   10 – 44 
Ribitol 18.1 9.3 5.9 12.8 8.3 7.4 7.8    n.d. – 5 
Mannitol 13.7 84.1 16.9 1038.4 73.1 957.3 11.2    3 – 61 
Sorbitol 8.2 2.9 6.6 9.7 2.4 1.8 2.9    2 – 26 
Galactitol 4.6 1.5 1.6 9.6 7.7 4.3 3.4   2 – 6 
Myo-inositol 16.4 3.7 21.8 23.0 11.1 9.1 3.9    2 – 23 
         
 
a
 Reference values according to age group 
 
The four patients that were subcategorized as AFLDb (Table 5) present an 
overall high excretion of the studied polyols. Patient 9, with a diagnosis of HCC, 
displays high excretion of erythritol, arabitol and ribitol, among other polyols, in the 
absence of sedoheptulose, pointing to some impairment at the level of the non-oxidative 
branch of the PPP. Patient 12, after the enrolment in this study, had a liver function 
deterioration and HCC was established. He displayed an increased excretion of arabitol, 
ribitol and threitol, and erythritol was near the higher value of the reference values. 
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Patient 2 presented with decompensated cirrhosis, but no progression to HCC was, until 
now, observed. His polyols’ profile showed high excretion of threitol, erythritol, ribitol 
and arabitol, also pointing to some impairment in the PPP. Once again mannitol and 
xylitol were excreted in high amounts, which may be attributed to drug intake. Patient 4 
showed no decompensated cirrhosis, but he had not stopped the ingestion of alcohol, 
therefore the observed polyols’ profile might be explained by that finding. This patient 
was the one that showed the highest excretion of arabitol and ribitol. None of these four 
patients presented sedoheptulose.  
 
Table 5. Urinary polyols results (mmol/mol Creat) of the AFLDb patients. Values presented in 
red are above the reference values. 
 
Polyol P2 P4 P9 P12 Reference Values 
a
 
  
 
   
Threitol 88.6 6.9 55.0 47.2  5 – 34 
Erythritol 98.5 38.4 124.6 74.1 19 – 76 
Xylitol 42.3 549.2 29.5 26.9             n.d. – 20 
Arabitol 108.5 111.0 99.9 71.2               10 – 44 
Ribitol 35.5 90.7 29.1 25.4             n.d. – 5 
Mannitol 264.9 63.7 1387.1 42.7   3 – 61 
Sorbitol 93.3 29.6 25.1 13.3   2 – 26 
Galactitol 17.6 1.9 5.9 9.3                 2 – 6 
Myo-inositol 20.2 28.9 11.7 13.5  2 – 23 
  
 
   
 
a
 Reference values according to age group 
 
 
As already referred in chapter 2, the PPP is strictly regulated and different 
mechanisms may be involved in this complex process. It is known that in many cancers 
these mechanisms may be disrupted and consequently the PPP will be disturbed. 
Therefore, we postulate that some mechanisms may also be affected in severe liver 
dysfunction which may justify the observed altered polyols’ profile in the two patients 
(P2 and P4) with severe liver dysfunction  
Transketolase (TKT) is, together with transaldolase, a key enzyme in the non-
oxidative branch of the PPP. As previously described, TKT is a thiamine diphosphate 
and Ca
2+
 ion dependent enzyme. Thiamine deficiency is a well documented effect of 
long-term alcohol abuse, therefore the abnormal metabolic findings observed in patient 
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4 may be ascribed to vitamin B1 deficiency. If thiamine levels are low, TKT may be 
unable of transferring C-1 and C-2 of Xu5P to R5P to form S7P and G3P, or vice versa; 
or to transfer the C-1 and C-2 of Xu5P to E4P to form G3P and F6P, or vice versa, 
leading to an impaired activity in the PPP and an overall accumulation of the 
intermediate metabolites.  
In patient 2, cirrhosis was present but in a decompensated form which can 
contribute for a more severe impairment of the PPP, leading to the observed 
accumulation of several polyols (Table 5). 
An overall high excretion of urinary polyols was detected in two of the patients 
(P9 and P12) with HCC. Transaldolase deficiency specific biomarkers, sedoheptulose 
and/or sedoheptitol, were not presented. Therefore, the hypothesis of a primary defect in 
the non-oxidative branch of the PPP was excluded. We may postulate that the 
accumulation of the polyols, in these two cases, is a secondary phenomenon resulting 
from the disruption of the regulatory mechanisms underlying the PPP. To clarify the 
possibility of polyol patterns having a diagnostic value in the characterization of liver 
dysfunction, further studies involving a larger cohort of patients are needed. Moreover, 
and concerning this clinical phenotype, it will be very interesting to evaluate the effect 
on specific enzymes of the PPP, such as G6PD, TKT and probably TKTL1, namely not 
only the respective enzymatic activities but also the protein levels. Due to the direct 
effect that the PPP deregulation may have in the level of NADPH and its implication on 
the maintenance of the ratio of reduced (GSH) / oxidated (GSSG) glutathione, cellular 
redox studies will be relevant to the better understanding of the underlying biochemical 
processes. 
All the studied 14 patients were under personalized therapeutic regimens 
according to their clinical situation. Therefore, some of the mild alterations, as well as 
some of the major ones, such as high excretion of xylitol and mannitol, components of 
drug`s excipients, may be explained by the use of drugs. 
In summary, in the light of these preliminary results, and although we have a 
small number of patients studied so far, we may postulate that an overall altered 
polyols’ profile may be related to liver disease progression and/or severity.  
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1. Introduction 
 
The pentose phosphate pathway (PPP) regained the attention of the scientific 
community after the description by Verhoeven and co-workers [1], in 2001, of the first 
patient with an inborn error of metabolism (IEM) in the non-oxidative branch of the 
PPP, a transaldolase (TALDO) deficiency.  
After the first reported case of TALDO deficiency, 22 other cases have been 
reported, until the present date [2-8]. The TALDO deficient patients described in the 
literature displayed a quite homogenous clinical picture: liver dysfunction (18/23), 
hepatosplenomegaly (22/23), anemia and thrombocytopenia (21/23), dysmorphic 
features (17/23) and cardiac problems (20/23). All patients (23/23) had direct or indirect 
hepatic alterations of unknown cause.  
Although the ribose-5-phosphate isomerase (RPI) deficient patient had no liver 
dysfunction or organomegalies, but rather presented a clinical picture of slowly 
progressive leukoencephalopathy of unknown origin, accompanied by mild peripheral 
polyneuropathy [9], it was the study of the PPP, and more specifically sugars’ and 
polyols’ pattern, that made the diagnosis possible. Also a benign condition, L-
arabinosuria, has been described in 2002, in a patient with dysmorphic features and no 
liver malfunction [10]. Although this is a benign condition, it was once again the study 
of the PPP metabolites that led to the diagnosis. 
Taking into account the clinical presentation of those new disorders, namely 
TALDO deficiency, the evaluation of urinary profiles of sugars and polyols in patients 
presenting liver dysfunction of unknown cause, became a valuable biochemical tool to 
unveil diagnosis and new defects associated with the PPP. In order to better understand 
the involvement of this metabolic pathway in liver dysfunction and to shed some light 
on pathologic significance of altered polyols’ profile, we studied a pediatric group with 
liver dysfunction of unknown cause. For that purpose, a joint protocol was established 
between our laboratory, Metabolism and Genetics, iMed.UL, at the Faculty of 
Pharmacy University of Lisbon and the Department of Metabolic Diseases at Pediatrics 
Hospital, at Coimbra. 
As far as we know, this is the first study in a Portuguese group of patients with 
liver dysfunction regarding the PPP metabolites. 
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2. Patients 
Since the beginning of this collaborative study (June 2012), 11 patients with 
hepatic dysfunction of unknown cause were enrolled. The first urine of the morning was 
collected during patients’ hospitalization or when they visited the clinician. Samples 
were immediately frozen, kept at – 20 ºC and sent in dry ice to the laboratory. Samples 
were kept frozen until time of analysis. Polyols and sugars were analyzed by GC-FID 
and/or GC-MS as previously described in chapter 3. 
 
Patient 1: a four-month-old girl. She presented clinically with extrahepatic 
biliary atresia. She was submitted to Kasai’s procedure, but the surgery was not able to 
restore the biliary atresia and her liver disease was rapidly progressing to hepatic 
failure. 
Patient 2: a seven-month-old girl. She was admitted in the Hospital due to a 
biliary atresia with portal hypertension leading to a cirrhotic liver development. At the 
date of sample collection, she was awaiting liver transplantation (LT). She also 
presented a cytomegalovirus (CMV) infection.  
Patient 3: a two-year-old girl. She presented with a congenital CMV infection 
with minor alterations of the transaminases levels (normal AST levels; slight elevation 
of ALT levels: 45-50; Ref. Val.: 10-25). She presented slight facial dysmorphic features. 
Hepatic biopsy revealed the presence of a slight fibrosis – sequelae of CMV infection. 
Abdominal echography revealed no morphological alterations of the liver and biliary 
tract. 
Patient 4: a five-year-old boy. He presented with hepatic dysfunction of 
unknown cause, dysmorphic features (low set ears, short neck, enlarged anterior-
posterior thorax), failure to thrive and psychomotor retardation, strabismus and ketotic 
hypoglycemia. 
Patient 5: a two-year-old boy. He was admitted with hepatic cirrhosis of 
unknown cause. He is currently awaiting LT. A brain nuclear magnetic resonance 
(NMR) showed calcification of several vertebral arteries. He had a hepatic biopsy 
analysis and the results were indicative of an autoimmune hepatitis. 
Patient 6: a twelve-year-old boy. He presented with hepatitis of unknown cause 
with high levels of copper, but with no criteria for Wilson’s disease. He had normal 
transaminases levels and a maintained discrete elevation of urea levels. He has 
complains of dizziness, even when lying down. 
Patient 7: a ten-year-old girl. She presented a chronic hepatitis of unknown 
cause. Her liver biopsy revealed a non-alcoholic steatohepatitis (NASH) with mild 
fibrosis. 
Patient 8: an eleven-year-old girl. She presented with short stature (136.5 cm; 
5-10 percentile) and weight (26.8 Kg; 5 percentile). She presented with elevated 
transaminases levels, however no organomegalies (liver and spleen within normal 
reference values) or signs of chronic liver dysfunction were observed. She has no intra- 
or extra-hepatic biliary atresia. Biochemically she presented normal levels of vitamin 
B12 and D, with a slight elevation of vitamin E. 
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Patient 9: a seventeen-year-old girl. She was admitted with an autoimmune 
hepatitis. She has short stature and psychomotor delay with peripheral polyneuropathy 
and optical neuropathy. 
Patient 10: a twelve-year-old girl. She presented with hepatomegaly, but with no 
hepatitis. She has no developmental delay. 
Patient 11: a twenty-one-month-old boy born after 35 weeks. He was admitted to 
the Hospital with a neonatal colestasis. He had frequent hypoglycemic episodes and 
growth retardation, including short stature as well as psychomotor retardation, failure 
to thrive, genital dysmorphism, large anterior fontanelle and macrocephaly (relative to 
stature). He also presented with anaemia, secondary hypocortisolism and diarrhea. He 
has had several childhood infections, but he does not seem to be immunodepressed. 
 
 
3. Results 
Patients were categorized into four groups according to their ages. Because the 
excretion of sugars and polyols vary throughout life, the urinary polyols concentrations 
displayed in Table 1 are correlated with age-matched reference values.  
Among the ten of the patients presented in Table 1 nine did not reveal major 
abnormalities in the polyols’ pattern. An interesting finding is that ribitol is elevated in 
6 of those patients (60%), being in half of them the only abnormal result.  
In patient 4, a slightly elevated excretion of arabitol was also noted. The 
presence of ribitol plus arabitol may suggest a mild impairment of the non-oxidative 
branch of the PPP. The urinary organic acids analysis revealed no alterations, but peaks 
of medication (acetaminophen and phenobarbital) were observed which may affect the 
normal PPP metabolism. New samples with the patient out of medication intake must be 
collected and analyzed for clarification of the obtained results. 
In patient 5, in addition to the elevated excretion of ribitol, a modest increase in 
sorbitol and galactitol levels was observed. The presence of these metabolites in 
moderated levels has been referred as a consequence and not as a primary cause of liver 
malfunction. Very interestingly, it was found in the urinary organic acids profile of this 
patient an elevated excretion of ethylmalonic acid, glutaric acid, 3-methyl-glutaric acid, 
3-methyl-glutataconic (I and II) acid and 3-hydroxi-3-methyl-glutaric acid, the 
hypothesis of a mild form of 3-hydroxy-3-methylglutaryl-CoA lyase deficiency was 
raised. The most common signs and symptoms of this condition are: vomiting; diarrhea;  
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dehydration; lethargy and hypotonia, yet none of these features were present in our 
patient. A new urine sample is needed to clarify the organic acids’ profile and also the 
carbohydrates’ profile. 
Patient 8 displays, in addition to the elevated excretion of ribitol, a slight 
elevation in xylitol and myo-inositol excretion. These alterations are only moderate and 
are not suggestive of a PPP impairment. No alterations were found in the organic acids’ 
profile. 
Although patient 9 presented no major alterations in the urinary polyols’ profile, 
we can observe a tendency to low values. The organic acids’ profile was assessed and it 
displayed a mild elevation in methylmalonic acid excretion (24 mmol/mol creatinine; 
Ref. Value: <5) and also a mild elevation in 3-methylcrotonylglycine. Taken together, 
these results do not point to an impairment of the PPP, or a specific organic aciduria, 
but rather a dietary deficiency in vitamins uptake. Further tests are needed to elucidate 
the organic acids’ profile. 
The patient with the most severe abnormalities in the polyols’ profile was patient 
2. She presented an elevation of all, except for myo-inositol, the studied polyols as well 
as in the group of sugars analyzed (data not shown). However, no sedoheptulose was 
found. Her urinary organic acids profile presented no major abnormalities, although 
many unidentified peaks were found (maybe due to patients’ therapeutic regimen). This 
polyols’ profile is quite similar to the ones of the four patients reported in chapter 4 with 
the most severe liver dysfunction. As previously referred (chapter 2, section 1.7) the 
PPP might be enhanced by one, several or a different mechanism, leading to the 
exacerbation of the PPP activity which may justify the observed pattern. Since the 
analysis of this sample, the patient was submitted to a LT. It would be of the utmost 
importance the evaluation of a new urine sample of the patient, in order to evaluate the 
sugars’ and polyols’ profile evolution. The collection of new samples has already been 
discussed with the patient’s clinician and in a near future it will be re-evaluated. 
The most interesting case was patient 11. Patient’s plasmatic acylcarnitines’ 
profile and urinary organic acids’ and purine and pyrimidines’ profile were assessed, 
and no alterations were found. The polyols’ results are presented in Table 2, and they 
reveal a strongly elevated excretion of the polyols: erythritol, arabitol and ribitol, plus 
galactitol and myo-inositol.  
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Table 2. Carbohydrates’ urinary concentration (mmol/mol creatinine) of 
patient 11 
 
Polyol P 11a P 11b 
Ref. Values  
(1-2 yrs) 
    
Threitol 70.1 37.3   15 – 122 
Erythritol 902.8 936.7   76 – 192 
Xylitol 16.7 17.4   7 – 29 
Arabitol 161.1 117.4 52 – 88 
Ribitol 41.1 23.9   9 – 24 
Mannitol 25.0 18.6       n.d. – 81 
Sorbitol 8.5 11.8   7 – 56 
Galactitol 86.3 70.9   7 – 22 
Myo-inositol 103.3 103.4 11 – 76 
Sedoheptulose   – 
    
 
The most striking result was the presence of an unknown peak with the retention 
time (RT) of the C7-sugar, sedoheptulose.  
The carbohydrates’ profile of this patient was compared with the one of an 
already diagnosed TALDO deficient patient (the sample was kindly supplied by Dr. 
Mirjam Wamelink). In figure 1 the carbohydrates’ chromatographic profile of both 
urine samples: (A) TALDO deficient patient and (B) patient 11, analyzed by GC-FID 
are showed. In figure 2 the carbohydrates’ chromatographic profile of both urine 
samples: (A) TALDO deficient patient and (B) patient 11, plus the mass spectrum from 
the unknown peak, analyzed by GC-MS, are displayed. The identity of the peak, as 
being sedoheptulose was confirmed. The biochemical results, together with the clinical 
symptoms (in agreement to what has been described in the literature for most TALDO 
deficient patients), guided us to the suspicion of a TALDO deficiency case.  
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Figure 1. Chromatographic carbohydrates’ profile of the TALDO deficient patient (A) and 
patient 11 (B). The analysis conditions are the same as shown in Figure 1 in Chapter 3, section 
3.3.1. The peak numbers correspond to the ones displayed in Figure 2 in Chapter 3, section 
4.1.2. Peak 34 was identified as sedoheptulose. 
 
 
To support the suspicion of TALDO deficiency further studies were necessary. 
To our knowledge, all described TALDO deficient patients presented increased 
excretion of the phosphate form of sedoheptulose, sedoheptulose-7-phosphate (S7P). 
Therefore, it was recognized as an important biomarker for TALDO deficiency. At the 
time of the development of this work, in our laboratory, it was not possible to evaluate 
S7P due to lack of proper methodology. Therefore, the patient’s urine samples were 
evaluated at the Metabolic laboratory, VU University Medical Center, by tandem mass 
spectrometry (LC-MS/MS), as described by Wamelink and co-workers [11,12]. 
Interestingly, no S7P was detected. 
Chapter 5 
92 
In light of these new findings, a new hypothesis of diagnosis was raised: 
sedoheptulokinase deficiency (SHPK). SHPK or CARKL (carbohydrate kinase-like) 
gene was first reported by Touchman and co-workers in 2000 [13], when they 
completely sequenced the genomic region encoding the Nephropathic Cystinosis 
(CTNS) gene. Nephropathic cystinosis is a rare autosomal recessive lysosomal storage 
disease (MIM# 219800) [14]. The most prevalent mutation is a large deletion of 57,257-
bp, accounting not only for the loss of cystinosin, (the integral membrane protein 
responsible for cystine transport) leading to cystine accumulation within lysosomes; but 
also the loss of cytoplasmatic CARKL protein (see Figure 3). 
 
Figure 3. Position and organization of the three genes TRPV1 (transient receptor 
potential cation channel subfamily V member 1), CARKL, and CTNS; and the most 
common cystinosis mutation (57-kb deletion). Adapted from Wamelink et al., 2008 
[78]. 
 
The CARKL gene is located in chromosome 17 (17p13 region), and is fully 
contained within the ~57-kb region most commonly deleted in nephropathic cystinosis 
patients. The CARKL protein was first identified as the SHPK protein, by Wamelink 
and co-workers in 2008 [15], when they studied the urinary sugars’ and polyols’ profile 
of 10 nephropathic cystinosis patients, and found elevated concentrations of 
sedoheptulose and erythritol in patients homozygous to the 57-kb deletion, when 
compared to heterozygous patients with other mutations or controls [15].  
SHPK catalyses the phosphorylation of sedoheptulose to sedoheptulose-7-
phosphate (S7P), being an important regulatory enzyme, responsible for the feeding of 
S7P molecules to the PPP. Effectively, this allows the reversible function of TALDO 
and/or TKT, when glyceraldehyde-3-phosphate arising from the glycolytic pathway is 
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used by the PPP, when increased amounts of NADPH and/or ribose moieties are needed 
for nucleotides production.  
The CARKL/SHPK gene was studied in collaboration with the VU University 
Medical Center. Total RNA was extracted from whole blood samples of the patient and 
his mother, reverse transcribed into cDNA and then PCR amplified. The open reading 
frame (ORF) of the SHPK gene and the splice sites have also been analyzed by 
sequence analysis of genomic DNA, and a nonsense mutation, c.355C>T (p.R119X), 
leading to a truncated non-functional protein, was found in homozygosity. The mother 
was found to be a carrier for the same mutation. DNA sample from the father was not 
available for mutational analysis. TALDO1 gene was also sequenced for differential 
diagnosis purpose, but no pathogenic mutations were detected. The activity of SHPK 
was measured in fibroblast homogenates and a strongly reduced formation of S7P was 
detected (2.9 nmol/hour/mg protein; controls 20-54), indicating SHPK deficiency.  To 
the present date, only two patients, the patient described above and a Dutch baby girl 
(Wamelink, personal communication), were found. Further tests are needed to fully 
characterize this patient, once the high frequency of this c.355C>T variant, 8/4292 
European control individuals (http://evs.gs.washington.edu/EVS/), does not suggest it 
might be responsible for an inborn error of PPP metabolism showing a severe 
phenotype. 
 
 
4. Final remarks 
 
The study of the urinary profile of sugars and polyols, as Verhoeven and co-
workers clearly shown, in 2001, is of the upmost importance not only for diagnostic 
purposes, but also for a better understanding of the cellular mechanisms. However, at 
present, the study of sugars’ and polyols’ profile is not yet done as a routine diagnostic 
workup in patients with liver disease of unknown cause. 
The evaluation of sugars and polyols among the group of selected patients 
revealed two interesting situations: patient 11 seems to possess a new inborn error of 
metabolism at the SHPK enzyme level. Until now, as much as we know, an isolated 
defect in the SHPK enzyme has never been described. Further studies are still in course 
to fully establish the defect and its link with the patient`s clinical phenotype. 
Furthermore, patient 2 revealed a very interesting profile associated with a severe form 
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of liver disease, which is in accordance with our previous observations concerning the 
adult patients (chapter 4). Further studies are necessary for the clarification of these 
cases. 
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Final remarks 
 
In the last 15 years the understanding of the biochemical alterations associated 
with disruption of the pentose phosphate pathway (PPP), due to primary or secondary 
causes, regained the attention of the scientific community with the description of two 
new inborn errors of metabolism in the non-oxidative branch of the PPP: ribose-5-
phosphate isomerase deficiency and transaldolase deficiency. Further attention has been 
paid to sugars’ and polyols’ profiles. Biomarkers, as well as chromatographic profiles 
for other specific defects in the PPP, such as L-arabinosuria and essential pentosuria, 
were established. The evaluation of sugars and polyols also became relevant for the 
diagnosis and follow up of therapeutic effectiveness of other carbohydrates related 
diseases (Diabetes Mellitus and Galactosemia), and also for the study of liver and 
kidney diseases of unknown cause.  
The development and validation of the GC-FID method described in chapter 3, 
was achieved with full success since the objectives were accomplished, i.e. excellent 
resolution and reproducibility of the chromatographic parameters and overall precision. 
Therefore, the optimized method fulfills the requirements to be used in the screening of 
PPP defects and to the study of metabolic disturbances in sugars and polyols pathways. 
The evaluation of the metabolic profiles, within the pediatric group of patients, 
unraveled a new disorder in the PPP: sedoheptulokinase (SHPK) deficiency.  Further 
studies seem to confirm the genetic defect and, to our knowledge, this is the first 
reported case of isolated SHPK deficiency. Interestingly, a second patient has now been 
found (Wamelink, personal communication). Nevertheless, the patients` clinical signs 
and symptoms are not fully coincident. So, the association of the genotype with the 
observed clinical phenotype needs to be clarified and additional studies are required. 
Moreover, the cross analysis of the results of the two studied groups, adults 
(chapter 4) and children (chapter 5) with liver dysfunction, pointed to an important 
role of sugars and polyols metabolites on the assessment of liver dysfunction 
progression and/or its severity. 
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Perspectives 
 
Taking together the work developed along chapters 3, 4 and 5 aiming to explore 
the role of the PPP biomarkers in metabolic dysfunction, several questions were raised 
that need to be answered, either from a strict analytical point of view or in the scope of 
the cellular mechanisms. This knowlegde will surely lead to a better understanding of 
the relationship between the altered PPP patterns and liver disease. 
The two groups of patients - adults and children - with liver dysfunction revealed 
interesting findings. The significance of the altered sugar and polyol pattern, observed 
in association with liver dysfunction progression and severity, needs to be evaluated in a 
largest cohort of patients. Only then, it will be possible to confirm or refute our 
preliminary results which allowed us to raise the hypothesis that polyols may be 
regarded as predictive biomarkers of progression of liver disease to hepatocellular 
carcinoma.  
The discovery of a new defect in the PPP, the isolated form of SHPK deficiency, 
clearly pointed to the relevance of the evaluation, as a first screening, of the urinary 
sugar and polyol metabolites in patients with liver dysfunction. Therefore, the analysis 
of those intermediates will be integrated into the screening panel of metabolic tests in 
course in the laboratory of Metabolism and Genetics at FFUL, contributing to the 
expansion of inborn errors of metabolism screening tests offered in Portugal. However, 
efforts need to be put on the development of analytical methods (HPLC or LC-MS/MS) 
that will allow the evaluation of sugar phosphate forms, since these compounds are 
crucial for the differential diagnosis among the PPP defects. Furthermore, the evaluation 
of some of the carbohydrates metabolites, such as galactitol and sorbitol, gained 
relevance in the control of galactosemia and diabetes mellitus therapeutic regimens, 
respectively. 
The importance of the PPP towards the redox status of the cell, as the leader 
pathway in the production of NADPH, clearly suggests that the study of redox status 
markers will be an area to be explored, aiming the better understanding of the cellular 
effects caused by PPP disruption. Furthermore, the processes involved in the PPP 
regulation are far from being fully understood. The PPP turns out to be a target of great 
interest in liver disease, including cancer, and the possibility of proceeding with this 
preliminary work is crucial and promising. 
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Annex 1. Urine Sample Preparation 
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Annex 2. Plasma Sample Preparation 
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Annex 3. Extraction protocol: Sugars and polyols trimethylsilylether derivatives  
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Annex 4. Optimization of the chromatographic resolution conditions 
 
 
 
 
 
 
 
 
 
 
 
 
A. Oven temperature program: starting at 120 ºC rising to 295 ºC in four steps, with 
a total run time of approximately 75 min/sample. 
 
 
 
 
 
 
 
 
 
 
Step Temperature (ºC) Rate (ºC/min) Time (min) 
i 120 1.5 0 
ii 156 4.0 0 
iii 265 10.0 0 
iv 295 - 20 
A 
120 ºC 
156 ºC 
265 ºC 
295 ºC 
1.5 ºC/min 
4.0 ºC/min 
10.0 ºC/min 
Annexes 
111 
100
150
200
250
300
0 10 20 30 40 50 60 70
T
e
m
p
e
r
a
tu
r
e
 (
ºC
)
Time (min)
Oven Temperature Program 3
 
 
 
 
 
 
 
 
 
 
 
 
 
B. Oven temperature program: starting at 130 ºC rising to 295 ºC in four steps, with 
a total run time of approximately 68 min/sample. 
 
 
 
 
 
 
 
 
 
 
Step Temperature (ºC) Rate (ºC/min) Time (min) 
i 130 1.5 0 
ii 156 4.0 0 
iii 265 10.0 0 
iv 295 - 20 
B 
130 ºC 
156 ºC 
265 ºC 
295 ºC 
1.5 ºC/min 
4.0 ºC/min 
10.0 ºC/min 
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C. Oven temperature program: starting at 140 ºC rising to 295 ºC in four steps, with 
a total run time of approximately 85 min/sample. 
 
 
 
 
 
 
 
 
 
 
 
Step Temperature (ºC) Rate (ºC/min) Time (min) 
i 140 1.5 0 
ii 156 4.0 0 
iii 265 10.0 0 
iv 295 - 30 
C 
140 ºC 
156 ºC 
265 ºC 
295 ºC 
1.5 ºC/min 
4.0 ºC/min 
10.0 ºC/min 
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Annex 5. Sugars and polyols calibration curves 
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